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THE FANCONI ANEMIA (FA)/DNA DAMAGE REPAIR PATHWAY IS 
REGULATED BY NF-B AND MEDIATES DRUG RESISTANCE IN MULTIPLE 
MYELOMA 
DANIELLE N. YARDE 
ABSTRACT 
  The Fanconi Anemia (FA)/BRCA DNA damage repair pathway plays a critical 
role in the cellular response to stress induced by DNA alkylating agents and greatly 
influences drug response in cancer treatment. We recently reported that FA/BRCA DNA 
damage repair pathway genes are overexpressed and causative for resistance in multiple 
myeloma (MM) cell lines selected for resistance to melphalan.  We hypothesized that the 
FA/BRCA DNA damage repair pathway mediates response and resistance to 
chemotherapeutic agents used to treat multiple myeloma and other cancers, and targeting 
this pathway is vital to overcoming drug resistance.   In this dissertation, we show that 
FA/BRCA pathway genes are collectively overexpressed in MM, prostate, and ovarian 
cancer cell lines selected for resistance to melphalan and cisplatin, respectively.  
Interestingly, cells selected for resistance to topoisomerase II inhibitors selectively 
overexpress only FANCF.  We also show that FA/BRCA pathway expression can be 
inhibited by the proteasome inhibitor bortezomib.  FA/BRCA pathway mRNA expression 
was inhibited by bortezomib in myeloma cell lines and patient samples.  FANCD2 gene 
and protein expression are downregulated by bortezomib, and remain attenuated in the 
face of melphalan treatment.  Melphalan-induced FANCD2 foci formation was also 
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inhibited by bortezomib, and this drug enhanced melphalan-induced DNA damage, likely 
via inhibition of FA-mediated DNA damage repair.  Next, we analyzed regulation of the 
FA/BRCA pathway.  We demonstrate that NF-B, specifically the RelB/p50 subunits, 
transcriptionally regulates members of the FA/BRCA pathway, and inhibition of these 
subunits by siRNA, BMS-345541, and bortezomib reduces FA/BRCA pathway 
expression.  Furthermore, knocking down RelB and p50 simultaneously attenuates 
FANCD2 protein expression and results in diminished DNA repair and enhanced 
sensitivity to melphalan.  Importantly, melphalan resistance was restored when FANCD2 
was re-expressed in these cells.  We also show that bortezomib regulates FANCD2 
protein expression directly, by inhibiting FANCD2 synthesis.  Finally, we demonstrate 
that low-dose bortezomib arrests cells in G0/G1 and also overcomes the S-phase arrest 
induced by melphalan, likely via inhibition of ATR.   
  Overall, our findings provide evidence for targeting the FA/BRCA pathway, 
either directly or indirectly, via inhibition of NF-B or ATR, to enhance 
chemotherapeutic response and reverse drug resistance in multiple myeloma and other 
cancers. 
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INTRODUCTION 
 Cancer is defined as a malignant growth caused by uncontrolled cell division and 
lack of programmed cell death.  In 2000, Hanahan and Weinberg identified six hallmarks 
of cancer, and suggested that these alterations within the cell dictate the origination of a 
malignancy (1).  These six characteristics are:  “self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis” (1).  Hematologic 
malignancies exhibit many, if not all, of these traits, and understanding the mechanisms 
of tumorigenesis and drug resistance is crucial to both diagnosing and finding a cure for 
these diseases.  
 Multiple myeloma is an incurable malignancy arising from a clonal population of 
plasma cells (2).  Although response to initial chemotherapy is typical, patients relapse 
due to the emergence of drug resistance.  Our lab and many others have focused 
extensively on the mechanisms of drug resistance in myeloma.  We previously reported 
that the FA/BRCA DNA damage repair pathway is associated with and causative for 
resistance to the DNA damaging agent melphalan (3-4).  This dissertation analyzes the 
transcriptional regulation of the FA/BRCA pathway and highlights the important role that 
this pathway plays in response and resistance to chemotherapeutic agents commonly used 
in the clinic to treat myeloma.  
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Hematologic Malignancies 
 The formation of new blood cells is termed hematopoiesis.  Pluripotent 
hematopoietic stem cells (HSCs) can give rise to both lymphoid and myeloid cells.  
Lymphoid progenitors, in turn, give rise to B and T cell lymphocytes, whereas myeloid 
and erythroid progenitors are responsible for the generation of macrophages, 
granulocytes and erythrocytes.  Hematopoiesis is a dynamic process involving numerous 
growth factors, cytokines, and microenvironmental stimuli.  Importantly, errors involving 
any of these homeostatic regulators can have detrimental effects, causing malignancies of 
these different cell lineages.  
Hematologic malignancies account for 9.5% of all cancers diagnosed in the 
United States (leukemia-lymphoma.org).  These diseases can be divided into two broad 
categories, based on whether they are derived from lymphoid or myeloid cell lineages.   
Lymphomas, the most common of the hematopoietic malignancies, are tumors that arise 
from lymphocytes.  Myeloma falls under the category of a lymphoma, as it is a 
malignancy of plasma cells.    Leukemia comprises the second type of hematologic 
malignancy, and occurs when the blood-forming tissues, or leukocytes, grow 
uncontrollably.   
Although profound advances have been made in the treatment of hematologic 
malignancies, many of these cancers remain incurable due to the effects of minimal 
residual disease (MRD) and the emergence of drug resistance.  Certain cancer cells can 
elicit mechanisms, such as the evasion of apoptosis or the overexpression of drug 
resistance genes, to avoid cell death and persist in the patient even after many rounds of 
chemotherapy.  Unfortunately, these patients relapse and eventually succumb to disease 
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due to these remaining, often initially undetectable, tumor cells.  Some of these cancer 
cells are intrinsically resistant to chemotherapeutic agents, while others become resistant 
to drugs throughout the course of treatment.   
 
Multiple Myeloma 
 According to the National Cancer Institute (http://www.cancer.gov), 20,580 new 
cases of multiple myeloma (MM) were diagnosed in the United States in 2009, and in the 
same year, 10,580 deaths were associated with this disease.  MM comprises nearly 15% 
of all hematologic malignancies (5), and is associated with roughly 2% of all cancer 
deaths in the United States (6-7), ranking it the second most common hematologic 
malignancy in this country.  The lifetime risk of someone in the United States developing 
myeloma is 1 in 161 (7), with an increased incidence in men versus women (a ratio of 
1.4:1, respectively), and also in African Americans as compared to Caucasians (8).  The 
median age of diagnosis of MM is 71 years (9-10), and these patients typically present 
with the symptoms of “fatigue, bone pain, and recurrent infections” (11).           
 Multiple myeloma is a neoplasm arising from a clonal population of mature B 
cells.  Patients with MM have large numbers of clonal antibody-secreting plasma cells in 
their bone marrow (2).  The diagnosis of this disease requires the bone marrow to be 
comprised of at least 10% plasma cells (11).  In comparison, the percentage of plasma 
cells in a healthy individual‟s bone marrow is less than 1% (12).  Other criteria for 
diagnosis include secretion of excessive monoclonal immunoglobulin (Ig; as detected in 
the urine or serum), and end-organ damage as characterized by “CRABI” 
(hypercalcemia, renal insufficiency, anemia and bone lesions, and increased infection 
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rate) (8, 11-12).  According to Nair et. al., the most common Ig isotype (M-component) 
found in MM patients is IgG, and prognostically, IgA and IgD are the least favorable 
(13).  Also, the 20-30% of patients who present with renal failure are considered to have 
a poor prognosis (10, 14). 
 The disease of MM is often preceded by a premalignant condition called 
monoclonal gammopathy of undetermined significance (MGUS).  Myeloma progresses in 
these patients, who have less than 10% clonal plasma cells in their bone marrow, less 
than 3 grams/deciliter of paraprotein,  and no myeloma-related end-organ damage 
(CRABI), at a rate of about 1% annually (8, 11, 15).  Once the disease progresses, 
myeloma can be subdivided into two categories:  asymptomatic (smoldering) and 
symptomatic (active).  Patients with asymptomatic myeloma display an increase in M-
protein concentration when compared to MGUS patients, but do not have the end-organ 
damage required for the diagnosis of symptomatic myeloma (8, 16). 
 Progression from MGUS to myeloma is believed to coincide with cytogenetic 
changes (11), and newly diagnosed MM patients present with an average of seven 
chromosomal abnormalities (12).  The most common translocation, seen in 50% of 
patients, involves the immunoglobulin heavy-chain locus (17).  These translocations 
usually involve partnering with chromosomes that encode for oncogenes, such as cyclin 
D1 and D3, fibroblast growth factor receptor 3 (fgfr3)/MMSET, c-maf, and mafB (18-20).  
Also, certain translocations and abnormalities are associated with more aggressive 
disease.  For example, patients with the del(13) or del(17p) abnormalities have shorter 
time to progression as well as decreased overall survival when compared to patients 
without these chromosomal deletions (21-22).  Recently, though, it was found that the 
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poor prognosis associated with del(13) and other high-risk translocations could be 
overcome in relapsed or refractory patients treated with the novel therapeutic agents 
lenalidomide and bortezomib (23). 
 Therapeutic options for MM patients have changed markedly in recent years.  The 
gold standard for treatment for decades has been melphalan plus prednisone (24).  
However, new agents, such as immunomodulatory drugs (thalidomide and lenalidomide) 
and proteasome inhibitors (bortezomib and second-generation derivatives), have recently 
been approved for myeloma treatment and have shown promise in the clinic, both alone 
and in the setting of combination chemotherapy (2, 25-28).  New therapeutic options 
have nearly doubled the median survival, with the greatest improvements in survival rates 
seen in younger patients (6, 29).      
 Unfortunately, even with the exciting new options available for the treatment of 
MM, the emergence of drug resistance remains the largest hurdle in curing this disease. 
Therefore, discovering therapeutic agents that target specific pathways aberrantly 
expressed in drug sensitive and drug resistant cells will be necessary to cure this disease. 
  
Multiple Myeloma and Drug Resistance 
 A number of drug resistance mechanisms have been described in multiple 
myeloma.  These mechanisms of resistance can be intrinsic, due to intercellular changes 
that confer drug resistance, or extrinsic, where growth factors and physical effectors in 
the tumor cell‟s microenvironment mediate resistance.  Furthermore, following 
chemotherapy, many tumors also become cross-resistant to other agents as well, a 
phenomenon known as the multi-drug resistance (MDR) phenotype (30).  MDR in 
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myeloma has been shown to be mediated by overexpression of the drug transporter 
proteins P-glycoprotein (P-gp), multidrug resistance protein 1 (MDR1), and lung 
resistance-related protein (LRP) (30-32). 
 Drug resistance in myeloma is also known to be mediated by alterations in 
apoptotic machinery within the cell.  For example, overexpression of Bcl-2, an anti-
apoptotic member of the Bcl-2 family of proteins, confers resistance to chemotherapeutic 
agents such as doxorubicin, dexamethasone, and bortezomib (33-34).  Additionally, the 
anti-apoptotic proteins Mcl-1 and Bcl-XL have also been shown to contribute to drug 
resistance (35-37).   
 Aside from changes in apoptotic proteins, intercellular changes in other pathways 
are also known to influence drug resistance in multiple myeloma.  For example, myeloma 
cells selected for resistance to melphalan by chronically exposing these cells to low doses 
of the drug display reduced DNA interstrand crosslinks and enhanced glutathione levels 
(38).  Importantly, inhibition of glutathione synthesis in these cells reversed drug 
resistance (38).  Furthermore, microarray analysis of these same melphalan resistant 
myeloma cells (8226/LR5 cells) revealed changes in over 1400 genes when compared to 
the drug sensitive cells (4).  Overexpression of members of the glutathione pathway, 
DNA damage repair pathways, and cholesterol synthesis pathway were observed in the 
melphalan resistant cells (4). 
 Drug resistance is also influenced by the tumor cell‟s microenvironment.  
Adhesion to physical factors in the environment causes a drug resistance phenotype 
known as cell adhesion-mediated drug resistance (CAM-DR) (39-40).  Adhesion of 
tumor cells to fibronectin (FN) via 1 integrins  causes a G1 cell cycle arrest due to 
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increased p27
kip1
 expression (40), and also enhances degradation of the pro-apoptotic 
Bcl-2 protein bim (40).  Adhesion to bone marrow stromal cells (BMSCs) also protects 
myeloma cells from melphalan-induced cell death, and this resistance has been linked to 
upregulation of the Notch-1 signaling pathway (41). 
 Finally, growth factors are known to influence drug resistance.  For example, 
interleukin (IL)-6 and insulin-like growth factor I (IGF-1), two cytokines produced in the 
bone marrow microenvironment, confer resistance to chemotherapeutic agents by 
blocking apoptotic stimuli and activating the PI3K/AKT MAPK pathways (37).  These 
growth factors are also known to regulate the activity of certain transcription factors, such 
as STAT3 and NF-B, which have been reported to enhance drug resistance (42-44).  
   
Multiple Myeloma and NF-B 
 The transcription factor nuclear factor-B (NF-B) consists of two proteins, each 
containing an N-terminal Rel homology domain (45).  NF-B can be a hetero- or 
homodimer of the subunits RelA, RelB, c-rel, p50 and p52 (46).  The NF-B dimers 
remain inactive in the cytoplasm by association with one of three inhibitors of NF-B 
(IB), specifically IB, IB, or IB, or with p105 or p100 (the precursors of p50 and 
p52, respectively) (47).  Following stimulation, IB subunits are phosphorylated at 
conserved serine residues by the IB kinase (IKK) complex, comprised of IKK, 
IKKand IKK/NEMO(48-49).  These phosphorylation events target the IB subunits 
for proteasomal degradation, leading to the release of the NF-B dimer and subsequent 
translocation into the nucleus (50).  Once inside the nucleus, NF-B initiates the 
transcription of its target genes.  (Figure 1).   
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Figure 1.  The NF-B pathway.  NF-B is a homo- or hetero-dimer of the subuinits 
RelA, RelB, c-Rel, p50 and p52.  IB sequesters these proteins in the cytoplasm.  
Following stimulation, the IKK complex is activated and phosphorylates IkB, targeting it 
for proteasomal degradation.  NF-B is then free to translocate to the nucleus and 
activate transcription of its target genes.    
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 NF-B is known to be activated by one of three major pathways.  The canonical 
pathway is typically induced in response to bacterial infection or to tumor necrosis factor 
(TNF)-and other inflammatory cytokines, and is usually associated with the activation 
of the p50/RelA heterodimer (51).  The second NF-B activating pathway is termed the 
alternative, or noncanoncial, pathway.  This pathway, associated with p52/RelB 
activation, is initiated by certain TNF receptor (TNFR) ligands, such as BAFF and 
lymphotoxin .  Finally, the atypical pathway provides a much slower and weaker  
NF-B response when compared to activation of the other two pathways, and is induced 
in response to DNA damage and reactive oxygen species (ROS) (52).  
 NF-B has been shown to regulate a plethora of genes involved in inflammation, 
proliferation, metastasis, angiogenesis, and apoptosis (53).  As such, activation of this 
family of transcription factors is commonly observed in many different cancers (42, 54).  
For example, NF-B has been reported to be constitutively activated in multiple 
myeloma (55).  In two separate reports, Annunziata et. al., and Keats et. al., observed a 
number of NF-B-activating gene mutations in myeloma cell lines as well as in primary 
myeloma patient samples (56-57).  Furthermore, the RelB and p50 NF-B subunits are 
upregulated following MM cell adhesion to the extracellular matrix protein fibronectin 
(FN) (58).  This report provides a link between NF-B and drug resistance, as adhesion 
to FN is known to cause a transient (de novo) drug resistance phenotype in these cells.  
Also highlighting the important role of the NF-B pathway in drug resistance, microarray 
analysis of the FN-adhered cells revealed overexpression of 11 NF-B-regulated genes 
(58).  Finally, NF-B has been found to be overexpressed in MM cell lines that have been 
selected for resistance to various chemotherapeutic agents (59), and NF-B levels have 
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been found to be elevated in response to chemotherapy as well as in patient samples 
collected at the time of relapse (37, 60-62).  Thus, inhibition of NF-B, using agents such 
as the proteasome inhibitor bortezomib, is likely vital for the successful treatment of 
multiple myeloma.       
 
The Proteasome and Proteasome Inhibition 
  Over 80% of proteins within the cell are degraded by the ubiquitin-proteasome 
system (63).  Proteins tagged with ubiquitin have different functions, dependent upon the 
type of ubiquitination.  Monoubiquitination, in which a single ubiquitin is attached to a 
single lysine residue, is important for such processes as endocytosis, DNA repair, and 
nuclear export of the protein (64-67).  Proteins can also be multiubiquitinated, or 
monoubiquitinated on several lysines, and these proteins can be involved in endocytosis 
and nuclear export as well (68).  Finally, proteins can also be polyubiquitinated.  Proteins 
covalently bound to a polyubiquitin via lysine 63 characteristically signals DNA repair or 
endocytosis, whereas a protein linked to an ubiquitin chain via lysine 48 is typically 
targeted for proteasomal degradation (68).   
  Three enzymes are involved in the ubiquitin tagging of a protein.  The E1 enzyme 
is known as the activating enzyme, as it utilizes ATP to activate the ubiquitin molecule 
by converting it to an E1-thiol-ester~ubiquitin moiety (69).  The ubiquitin-conjugating E2 
enzyme transfers the active ubiquitin from the E2 to the E3 enzyme.  Finally, the E3 
enzyme, which functions as a ligase, conjugates ubiquitin to the target protein (69).  
(Figure 2). 
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Figure 2.  Ubiquitination and the proteasome.  Polyubiquitination of proteins leads to 
their subsequent degradation by the proteasome.  The E1 enzyme activates ubiquitin and 
transfers this molecule to the E2 conjugating enzyme.  E2 then transfers the active 
ubiquitin to the E3 ligase, which in turn conjugates ubiquitin to the target protein.  The 
E3 ligase also ligates ubiquitin molecules to one another, forming a polyubiquitin chain.  
Polyubiquitinated proteins are degraded by the 26S proteasome, which is comprised of 
the 19S regulatory caps (green) and the 20S core particle (brown), and the ubiquitin is 
recycled.  
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  Once polyubiquitinated, most proteins are targeted for proteasomal degradation.  
There are approximately 30,000 proteasomes in a single cell, which are located in the 
cytosol as well as in the nucleus (70-71).  The barrel-shaped 26S proteasome is formed 
by the 20S core particle and two 19S regulatory particles that cap each end (69).  The 20S 
core particle is responsible for the catalytic activity of the proteasome, and contains two 
outer  rings plus two inner  rings (69).  1, 2,and 5 are responsible for the caspase-
like, tryptic-like, and chymotryptic-like enzymatic activity of the 20S subunit (70).  The 
19S caps contain a base of six ATPase subunits and two non-ATPase subunits and a lid 
composed of 12 non-ATPase subunits (72).  These caps recognize and unfold 
polyubiquitinated proteins, open the  rings of the 20S subunit, and cleave and recycle 
the polyubiquitin chains (72).  (Figure 2).  
  Proteasomal degradation leads to the generation of polypeptides 3-23 amino acids 
in length, which are rapidly hydrolyzed by downstream proteases (69, 73).  This 
controlled degradation of proteins is vital for the regulation of many cellular processes, 
including apoptosis, cell cycle progression, DNA repair and transcription (72).  As 
mentioned above, NF-B activation is dependent upon proteasomal degradation of its 
inhibitor (50).  The proteasome is also responsible for the degradation of p53, the cyclin-
dependent kinase inhibitors p21
cip1/waf1 
and p27
kip1
, and the proapoptotic protein bim (70, 
74-75), and this degradation is necessary for cancer cell development and progression 
(76).  Therefore, inhibiting the proteasome as a means to stabilize these and other 
proteins seems promising for the treatment of cancer.                                      
  Bortezomib (PS-341; Velcade), a dipeptidyl boronic acid, is a reversible inhibitor 
of the 26S proteasome (77).  Bortezomib is an active, recently approved FDA agent, that 
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is being studied in combination with other drugs (26).  Two independent labs have 
reported that bortezomib enhances melphalan response in myeloma cell lines, implicating 
NF-B inhibition due to inhibited IB degradation in this enhanced response (59, 78).  
Furthermore, bortezomib in combination with melphalan has shown encouraging activity 
in myeloma patients in a Phase I/II trial (25).  Also, in a separate, multicenter Phase I/II 
study, the combination of bortezomib plus melphalan and prednisone was shown to be 
 highly effective, even in patients with poor prognostic factors, and a Phase III trial is 
now ongoing (27, 79-80).  
  Although bortezomib shows great promise in the clinic for the treatment of MM, 
approximately 20% of newly diagnosed patients are inherently resistant to the drug, and 
all others will develop resistance over time (29).  To this end, second-generation drugs 
such as carfilzomib and NPI-0052, which irreversibly inhibit the proteasome, are 
currently being tested in the clinic and have been shown to overcome boretezomib 
resistance (29, 81).  Due to the complexity of drug resistance mechanisms, however, it is 
likely that the most durable responses will result from the development of rational drug 
combinations that capitalize on synergistic interactions.    
 
DNA Damage 
 As mentioned above, bortezomib was only recently approved for the treatment of 
MM (77).  Prior to bortezomib, the gold standard for treating myeloma for many years 
had been melphalan, and this cytotoxic agent remains the drug of choice for high dose 
chemotherapy (24).  Melphalan, as well as an arsenal of other agents used in the clinic 
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today to treat cancers such as MM, targets tumor cells by damaging the DNA within 
these cells. 
 DNA within a cell can be damaged by endogenous means, such as by reactions 
that produce reactive oxygen and nitrogen species or by spontaneous hydrolysis reactions 
(82).  Furthermore, DNA can also be damaged by exogenous forces such as ionizing 
radiation, ultraviolet light, and chemotherapeutic agents (82).  In fact, it has been 
estimated that a single cell receives up to 10
5
 lesions per day (83).  Fortunately, cells are 
able to efficiently repair DNA via several different mechanisms as a means to maintain 
genomic integrity.  Conversely, genomic instability caused by defective DNA damage 
repair is a hallmark of cancer, reinforcing the fact that DNA must be repaired properly in 
order to maintain cellular homeostasis. 
 A cell can respond to DNA damage using a number of mechanisms to repair the 
DNA, based on the type and extent of damage.  Repair of damage involves activation of 
repair enzymes, numerous phosphorylation events, and recruitment of proteins to the site 
of damage (84).  Base excision repair (BER), for example, removes oxidative lesions and 
other DNA modifications by removing the erroneous base and recruiting polymerase and 
ligase proteins to repair the damaged strand (85).  DNA adducts and damage induced by 
ultraviolet rays, both of which distort the helix, is resolved by nucleotide excision repair 
(NER) (86).  During this process, which involves greater than 30 proteins, the damaged 
nucleotide is removed and the complementary strand is used as a template for repair (87-
88).  Also, lesions can be bypassed by a system termed translesion synthesis (TLS), 
which is not an ideal method of repair as it induces error and thus is mutagenic (82).  
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 DNA damage causing double strand breaks (DSBs) can induce a cell cycle 
checkpoint response leading to cell cycle arrest, and can also activate DNA damage 
repair or apoptotic pathways (84).  If the damage can be reversed, the mechanism of 
repair is classically either nonhomologous end joining (NHEJ) or homologous 
recombination (HR) (89).  NHEJ is typically initiated if the damage occurs when cells are 
in the G1 or early S phase of the cell cycle, whereas HR usually occurs during late S and 
G2 phases (88).  As with other DNA damage repair pathways, NHEJ requires a large 
number of proteins to facilitate effective repair.  Briefly, the heterodimer Ku70/Ku80 
binds to the site of damage, which leads to the recruitment DNA-PKCS and subsequent 
formation of a molecular bridge by the two strands (90).  Overhangs are then filled in or 
removed by polymerases or nucleases, respectively, and a ligase, namely ligase 
IV/XRCC4, repairs the break (88).  Due to the lack of a homologous strand as a template, 
NHEJ induces more errors than does HR. 
 Homologous recombination, a process integral for DSB repair as well as recovery 
of stalled replication forks, tends to be error-free as it uses an identical sister chromatid as 
a template to repair the damage (91-92).  Once a DSB is induced, the histone variant 
H2AX is phosphorylated (a commonly used marker of DSBs), and the ATM kinase is 
activated and phosphorylates a number of proteins integral to DNA repair (93-94).  Also, 
a complex containing Mre11, Rad50 and NBS1, known as the MRN complex, senses and 
binds to the site of damage (94).  This complex resects the ends of the DNA, and the 
single-stranded DNA coated with RPA and Rad proteins then invades the homologous, 
undamaged DNA (94).  Finally, DNA synthesis occurs using the homologous strand as 
the template (82).    
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 The DNA damage repair pathways described above were explained singularly.  It 
is important to note, however, that there is often much overlap between and among 
pathways when DNA damage takes place.  For example, although NHEJ typically occurs 
in the G1 and early S phases, it has also been shown to be activated at different stages of 
the cell cycle as well (95).  Also, inhibition of proteins known to be involved in the NER 
pathway led to ineffective DSB repair via NHEJ (88, 96).  Finally, the efficient repair of 
DNA interstrand crosslinks has been shown to involve the NER, HR and TLS pathways 
(93).       
 DNA interstrand crosslinks (ICLs), which can be induced by chemotherapeutic 
agents such as melphalan and cis-platinum, cause some of the most detrimental damage 
to the DNA as they covalently link both strands, effectively inhibiting replication as well 
as transcription (97-98).  DNA ICLs are first recognized and incised by NER proteins, 
such as ERCC1/XPF (99).  This incision leads to a DSB, which is then resected and 
strand invasion occurs, ultimately leading the repair via HR (89).  Throughout the process 
of ICL repair, numerous proteins are assembled at the damaged site, and the loading of 
these proteins onto the chromatin is coordinated by the Fanconi Anemia (FA)/BRCA 
DNA damage repair pathway (89, 93).  This pathway and the critical role it plays in DNA 
damage repair is discussed in detail in a later section.     
 Based on the vital role that DNA damage repair mechanisms play in maintaining 
genomic stability, it is easy to see why toxically damaging the DNA of cancerous cells 
and inhibiting DNA repair pathways in these cells has proven to be an effective means of 
killing tumors.  Conversely, it is understandable that defects in any of these repair 
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pathways can cause numerous problems, actually giving rise to cancer and other diseases 
that predispose to cancer.   
   
Diseases of Defective DNA Damage Repair 
 Defects and mutations in DNA damage repair pathway genes are known to be 
causative for a number of diseases and, because of the genomic instability inherent in 
cells with ineffective repair mechanisms, these diseases are known to be associated with a 
high propensity for developing cancer.  The cells of ataxia telangiectasia (A-T) patients, 
for example, do not express ATM, leading to impaired cell cycle checkpoints and 
genomic instability, typically resulting in a translocation between chromosomes 7 and 14 
(100-101).  A-T is characterized by such symptoms as progressive ataxia and impaired 
articulation, as well as a predisposition to lymphoma (101).  As another example, patients 
with Li-Fraumeni syndrome develop a wide variety of tumors at an early age (101).  This 
disease is caused by mutations in p53, a protein activated in response to DNA damage 
and involved in cell cycle regulation as well as in NER (101).  Likewise, patients with 
Xeroderma  pigmentosum (XP), caused by mutations in NER pathway genes, develop 
basal cell carcinoma at a greater than 1000-fold rate than that of the general population; 
and those with Nijmegen breakage syndrome (NBS), who have MRN complex defects, 
are predisposed to lymphoma (101-103). 
 Fanconi anemia (FA) was first described in 1927 and is reported to have a 1 in 
300 carrier frequency, with a median age of survival of only 23 years (104).  This 
disease, an autosomal recessive or X-linked disorder, is caused by defects in any of 13 
known FA genes.  As mentioned above, this pathway is integral in coordinating HR, 
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NER and TLS (93).  FA is characterized by congenital malformations, pancytopenia, and 
hypopigmentation (105).  This disease can also detrimentally affect the cardiac, renal and 
gastrointestinal systems (105).  Furthermore, patients present with hematologic problems 
at a median age of seven years old, and 90% of these patients develop bone marrow 
failure by the age of 40 (104).   
 The cells of FA patients are hypersensitive to DNA damaging agents such as 
diepoxybutane (DEB) or mitomycin c, and chromosomal breakage analysis using these 
agents is used as a diagnostic tool for this disease (106).  The chromosomal instability 
seen in FA patients predisposes them to cancer, with a median age of onset at just 14 
years of age (105).  Patients with the FA-D1 and –N subtypes are the most severely 
affected, with early onset of tumors and a “cumulative incidence probability of 
malignany” of 97% by a little over five years of age (107-108).  Conversely, all FA 
patients who survive past 50 are of the subtype FA-A (108), suggesting that this is the 
least severe genotype.  Finally, as a whole, over 50% of FA patients will develop AML 
by the age of 50, and they also have up to a 700-fold increased incidence of developing 
head and neck SCC when compared to the overall population (104, 109).  The high 
propensity for cancer development in FA patients underscores the vital role that the 
FA/BRCA DNA damage repair pathway plays in maintaining genomic integrity.                 
 
The Fanconi Anemia (FA)/BRCA DNA Damage Repair Pathway 
  Members of the FA/BRCA DNA damage repair pathway have been identified 
using complementation studies in patients with Fanconi anemia.  Thirteen FA 
complementation groups have been identified from these studies, and all 13 genes 
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(FANC A, B, C, D1, D2, E, F, G, I, J, L, M, and N) have since been cloned via 
complementation cloning, positional cloning or protein association (110-123).  As 
mentioned above, this pathway has been shown to be important for DNA damage repair 
via HR, NER and TLS (93).  A summary of each of these 13 genes is provided in Table 
1, and a depiction of this pathway in relation to HR is portrayed in Figure 3.   
 
Upstream FA Core Complex 
  Eight FA proteins (FANC A, B, C, E, F, G, L, and M) two Fanconi anemia 
associated proteins (FAAP24 and FAAP100), and Hes1 form a complex in the nucleus,  
termed the Fanconi anemia core complex (105, 124-127).  The main function of the core 
complex is to monoubiquitinate FANCD2 and FANCI, and all components of this 
complex must be intact in order for the monoubiqutination/activation of FANCD2 and 
FANCI and consequent facilitation of DNA damage repair (99, 128).  Furthermore, 
functions for some of these proteins beyond the realm of FA pathway activation have also 
been described. 
  FANCA interacts with FANCG and FANCL, and phosphorylation of FANCA is 
required for its accumulation in the nucleus (126, 129).  FANCB and FANCL are also 
important for the nuclear accumulation of FANCA (126).  ATR has been shown to 
phosphorylate FANCA and, outside of the FA core complex, this protein has also been 
found to be associated with the IKK signalsome as well as the SWI/SNF complex, the 
NER protein XPF, and the centromere –associated protein E (CENP-E) (105, 130-132).  
Finally, FANCA also associates with the chaperone protein Hsp90, and disruption of this  
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Gene Year cloned Location Involvement in FA pathway
FANCA 1992 16q24.3 FA core complex subunit
FANCB 2004 Xp22.2 FA core complex subunit
FANCC 1996 9q22.3 FA core complex subunit
FANCD1/BRCA2 2004 13q12.3 Interacts with Rad51
FANCD2 2001 3p26 Monoubiquitinatedby core complex
FANCE 2000 6p21.3 FA core complex subunit
FANCF 2000 11p15 FA core complex; flexible adaptor protein
FANCG 1998 9p13 FA core complex subunit
FANCI 2007 15q26.1 Monoubiquitinatedby core complex
FANCJ/BRIP1 2005 17q22-24 Helicase
FANCL 2003 2p16.1 FA core complex subunit, E3 ligase
FANCM 2005 14q21.3 FA core complex, translocase, ATR activator
FANCN/PALB2 2007 16p12.1 Stabilizes BRCA2
 
 
Table 1.  Overview of FA pathway members.  
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Figure 3.  The FABRCA DNA damage repair pathway.   Eight FA subunits, two 
Fanconi anemia-associated proteins, and Hes1 form the upstream FA core complex (in 
green).  Intact core complex monoubiquitinates and thus activate FANCD2 and FANCI 
via the E3 ligase activity of FANCL.  The ID complex (brown) in turn interacts with FA 
proteins downstream of the core complex (blue) to initiate DNA damage repair via 
homologous recombination.  Phosphorylation of FANCA, FANCD2, FANCI, and 
FANCM by ATR is also required for activation of this pathway.  UBE2T is the E2 
enzyme involved in the monoubiquitination events, and USP1 functions as a negative 
regulator of this pathway by deubiquitinating FANCD2 and FANCI.  FANCM loads the 
core complex on the chromatin and also activates ATR.   
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interaction results in proteasomal degradation of FANCA and export to the cytoplasm 
(133). 
  FANCB, which is the only X-linked FA gene, associates with FANCL in the core 
complex and, along with FANCG and FANCM, stabilizes the interaction between 
FANCL and FANCA (116, 126).  The stability of both FANCB and FANCL is mediated 
by association with FAAP100, as the formation of a FANCB/FANCL/FAAP100 complex 
protects all three of these proteins for degradation (125).   
  FANCC is located primarily in the cytoplasm, but can be recruited to the nucleus 
via its binding partner, FANCE (134-136).  Interestingly, the levels of FANCC mRNA 
are constant throughout the cell cycle, but FANCC protein is proteasomally degraded in a 
cell cycle-dependent manner (137).  This protein has been linked to DSB repair 
mechanisms, as it is necessary for mitomycin c-induced MRN foci formation (138).  
Separate from its role in the FA core complex and MRN foci formation, FANCC is also 
necessary for maintenance of the G2/M checkpoint, is required for optimal STAT 
activation, has been found to interact with Hsp70, and can prevent apoptosis of 
hematopoietic cells by enhancing the enzymatic activity of glutathione S-transferase P1-1 
(GSTP1) (139-142).        
  FANCC nuclear accumulation is regulated by FANCE, and the converse is also 
true (135).  FANCE is also a partner of FANCD2, and is known to arbitrate the 
interaction between this protein and FANCC, as well as between FANCC and FANCF 
(143).  FANCE and other core complex members must be functional to activate DNA 
damage repair via the FA/BRCA pathway.  Interestingly, following DNA damage, 
phosphorylation of FANCE at threonine 346 and serine 374 by Chk1 leads to its 
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degradation (144).  Therefore, phosphorylation of FANCE following DNA damage is 
postulated as one way in which the FA/BRCA pathway is negatively regulated (144). 
  The fifth subunit of the FA core complex is FANCF.  Leveille et. al. identified 
this protein as a “flexible adaptor protein” (145).  The N-terminal region of this protein 
stabilizes the interaction between FANCA and FANCG and between FANCC and E, and 
FANCG also binds directly to the C-terminal region of FANCF (145). 
  Phosphorylation of the FANCG protein by ATR is required for the direct 
interaction between FANCD2 and BRCA2, and FANCG also promotes formation of a 
complex between these two proteins and the Rad51 paralog XRCC3 (146).  Interestingly, 
Wilson et. al. found that FANCG and XRCC3 were epistatic for mitomycin c sensitivity, 
providing another link to the FA/BRCA pathway and HR repair (146). 
  FANCL is one of the key mediators of FANCD2/I monoubiquitination.  This 
protein, which binds to other FA core complex proteins via its WD40 repeats, is reported 
to have E3 ligase activity (115, 147).  The PHD/RING finger motifs of FANCL allow it 
to recruit UBE2T, the E2 enzyme, to facilitate monoubiquitination (148). 
  Finally, FANCM is the most recently identified member of the FA core complex.  
This protein has an N-terminal helicase-ATPase domain and a C-terminal endonuclease 
domain (117).  FANCM displays a high affinity for branched DNA structures and likely 
plays a role in replication fork remodeling (149).  FANCM forms a stable complex with 
FAAP24 that binds to chromatin in response to DNA damage or during cell cycle 
progression, and recruits the core complex to the chromatin during S-phase (150-151).  
FANCM is phosphorylated by Plk1, ATM or ATR, and hyperphosphorylation and 
subsequent degradation of FANCM following replication releases the FA core complex 
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from the chromatin (151-152).  In Xenopus egg extracts, Sobeck et. al. found that binding 
of xFANCM to the chromatin and subsequent phosphorylation of FANCM was 
dependent upon FANCD2 (151).  Conversely, FANCM is required for FANCD2 
monoubiquitination (153).  Also, FANCM and FAAP24 interact with the checkpoint 
protein HCLK2 and regulate ATR signaling in a manner independent of the FA pathway 
(154).                     
 
ID Complex 
  Each of the upstream core components described above must be intact and 
functional in order for the activation/monoubiquitination of FANCD2 and FANCI to 
occur.  These two proteins stabilize one another and are known as the ID complex (120).  
The ubiquitination of FANCI is important for the maintenance of ubiquitination on 
FANCD2, and vice versa (120).  FANCI phosphorylation by ATR is also necessary for 
FANCD2 activation (155), and ATR-mediated phosphorylation of FANCD2 is necessary 
for DNA damage-induced foci formation (64).   
  Following monoubiquitination, the FANCD2/FANCI complex translocates to 
sites of damaged chromatin.  Here, FANCD2 has been shown to interact with proteins 
such as BRCA1 and RAD51 in an S-phase-specific manner (156), BRCA2 and 
PCNA(157), and NBS1 (158).  It is believed that FANCD2 and its interaction with these 
proteins initiates DNA repair via homologous recombination (128, 159).  The FA/BRCA 
pathway has also been implicated in translesion synthesis repair (128, 160), and 
phosphorylation of FANCD2 by ATM/ATR has also been shown to initiate an inter-S-
phase cell cycle checkpoint (64, 161).  FANCD2 is deubiquitinated and thus inactivated 
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by the USP1 enzyme (162).  Importantly, DNA crosslink repair occurs only after 
FANCD2 is deubiquitinated (163). 
 
FA Proteins Downstream of ID 
  Finally, three FA proteins, FANCD1/BRCA2, FANCJ and FANCN, function 
downstream of the ID complex.  Like FANCM, FANCJ also has helicase and ATPase 
activity (164).  Sommers et. al. found that this ATP hydrolysis via FANCJ can destabilize 
protein/DNA complexes, FANCJ can control HR repair via inhibition of RAD51 strand 
exchange, and may also remove DNA structures that would inhibit efficient repair (165-
166).           
  FANCN/PALB2, a breast cancer predisposition gene, interacts with and is 
essential for the stability of the tumor suppressor gene BRCA2 (167).  FANCN also 
promotes the interaction between BRCA1 and BRCA2 (168).  BRCA2 is important for 
loading RAD51 to the site of DNA damage, thus initiating HR repair (165).       
  In summary, the FA core complex is essential for the monoubiquitination of the 
ID complex members, and this activation event leads to interactions with numerous 
proteins and the initiation of DNA damage repair. 
 
FA/BRCA Pathway and Drug Resistance 
  As described above, the FA/BRCA DNA damage repair pathway is complex and 
requires the coordinated efforts of numerous proteins for proper function.  Defects in the 
FA/BRCA DNA damage repair pathway lead to genomic instability, which can 
ultimately give rise to cancers (105).  Conversely, enhanced expression of this pathway 
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can lead to resistance of tumor cells to chemotherapeutic agents.  Our lab was the first to 
show overexpression of FA/BRCA pathway genes (4).  Gene expression profile analysis 
performed by our lab revealed that two FA/BRCA DNA damage repair genes (fancf and 
rad51c) were overexpressed in cells selected for resistance to melphalan when compared 
to the drug sensitive parent cell line (4).  Further investigation of this pathway, using the 
more sensitive method of q-PCR, showed that many FA/BRCA pathway genes are 
overexpressed in two melphalan resistant myeloma cell lines when compared to the drug 
sensitive cell lines (3).  Importantly, using siRNA techniques to knock-down FANCF, 
Chen et. al. demonstrated a causal relationship between levels of FANCF and melphalan 
response.  Furthermore, overexpressing FANCF in the drug sensitive cell line conferred 
resistance to melphalan (3).  Also, in a separate study using a different melphalan 
resistant MM cell line, Xiao et. al. found that resistance to melphalan could be reversed 
via inhibition of FANCD2 activation with the natural agent curcumin (169).   
  The FA/BRCA pathway has also been found to be important in drug resistance in 
other cancer types.  Treatment of a FANCF-deficient ovarian cancer cell line with 
temozolomide (TMZ) or BCNU caused enhanced cytotoxicity in these cells when 
compared to the isogenic FANCF-corrected cell line (170).  Also, FA-proficient glioma 
cell lines were determined to be more resistant to TMZ and BCNU when compared to a 
glioma cell line that was FA-deficient, and inhibition of the FA pathway increased drug 
sensitivity (170).  Furthermore, the histone deacetylase (HDAC) inhibitor phenylbutyrate 
was found to enhance the sensitivity of head and neck cancer cells to cisplatin via 
inhibition of BRCA1 (171), and non-small-cell lung cancer cells were sensitized to 
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cisplatin following transfection with an adenovirus expressing a dominant-negative form 
of FANCA (172).   
  Interestingly, FA/BRCA pathway inactivation followed by re-activation has been 
reported in tumors when analyzing these cells before and after treatment.  Alan 
D‟Andrea‟s group, for example, reported that FANCF was methylated, and thus inactive, 
in ovarian tumors, and subsequently demethylated/activated upon acquisition of cisplatin 
resistance (173).  Also, analysis of ovarian cancer cell lines and patient specimens 
revealed secondary mutations in BRCA2 following drug treatment, leading to restored 
BRCA2 function and cisplatin resistance (174-175).  Overall, the FA/BRCA pathway has 
been linked to drug resistance in a variety of tumor types and thus should be considered 
an important target for overcoming drug resistance.            
 
The FA/BRCA Pathway is Regulated by NF-B and Mediates Drug  Resistance in 
Multiple Myeloma 
 Due to the complexity of drug resistance and DNA damage repair mechanisms, it 
is likely that the most durable chemotherapeutic responses will result from the 
development of rational drug combinations that capitalize on synergistic interactions.  
The main hypothesis of all work presented in this dissertation is that the FA/BRCA 
DNA damage repair pathway mediates resistance to chemotherapeutic agents used 
to treat multiple myeloma and other cancers, and targeting this pathway is vital to 
overcome drug resistance.     
 As mentioned above, we recently reported that the FA/BRCA DNA damage 
repair pathway is causative for resistance to melphalan in MM cell lines (3-4).  The goal 
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of Part I of this dissertation was to determine the extent of FA/BRCA pathway 
involvement in drug resistance, including both alkylating and non-alkylating agents, and 
in different tumor types.  We analyzed FA/BRCA pathway mRNA expression in a 
prostate cancer model selected for resistance to melphalan and an ovarian cancer cell line 
selected for resistance to cisplatin.  Substantiating the results that we have seen in the 
melphalan resistant MM cell lines, we show that both resistant cell lines also overexpress 
FA/BRCA pathway genes when compared to their respective isogenic drug sensitive 
parent cell line.  Furthermore, we analyzed FA/BRCA pathway expression in 8226 cells 
selected for resistance to two topoisomerase II inhibitors, doxorubicin and mitoxantrone.  
Interestingly, we did not see global overexpression of FA/BRCA pathway genes.  These 
drug resistant cells, however, were found to selectively overexpress FANCF. 
 We next wanted to determine if chemotherapeutic agents could be used to 
downregulate FA/BRCA pathway expression and thus reverse resistance.  To this end, we 
analyzed FA/BRCA pathway expression following treatment with the proteasome 
inhibitor bortezomib.  Bortezomib has been shown to enhance melphalan response both 
in vitro and in vivo (28, 59, 78), but the mechanism by which this occurs is largely 
unknown.  Also, Taniguchi‟s group has reported that proteasome function is necessary 
for FA/BRCA pathway activation (176).  Based on these findings, we hypothesized that 
bortezomib enhances melphalan cytotoxicity via inhibition of the FA/BRCA pathway.  
The experiments performed in Part II of this dissertation test this hypothesis.  We 
analyzed FA/BRCA pathway mRNA expression in MM cell lines as well as MM primary 
specimens following bortezomib treatment and found that bortezomib does indeed inhibit 
FA/BRCA pathway expression.  We also found that bortezomib can inhibit FANCD2 
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mRNA and protein expression, even in the presence of melphalan, and it can also inhibit 
melphalan-induced FANCD2 foci formation.  Using the alkaline comet assay, we also 
show that bortezomib enhances melphalan-induced ICL formation, likely through 
inhibition of DNA damage repair mediated by the FA/BRCA pathway. 
 The experiments in Parts III and IV of this dissertation further investigate the 
regulation of the FA/BRCA pathway.  First, we hypothesized that NF-B 
transcriptionally regulates members of the FA/BRCA pathway.  This hypothesis is based 
on our knowledge that NF-B activity is constitutively activated in MM cells and is 
further overexpressed in drug resistant cells as well as at time of relapse (56-59).  Also, 
our lab previously reported that the DNA binding activity of the RelB and p50 subunits is 
enhanced in MM cells displaying a drug resistance phenotype via adhesion to fibronectin 
(58).  Part III of this dissertation shows that NF-B, specifically the RelB/p50 subunits, 
does indeed regulate FA/BRCA pathway transcription.  Furthermore, inhibition of 
RelB/p50 reversed melphalan resistance, and this reversal was overcome by re-
expressing FANCD2 in these cells. 
 Next, because we found that FA/BRCA pathway mRNA expression was 
attenuated by bortezomib, but not to the same extent as the inhibition of FANCD2 protein 
expression, we hypothesized that bortezomib has a direct effect on FANCD2 protein 
expression.  Therefore, we analyzed FANCD2 protein stability via stable isotopic 
labeling of amino acids in cell culture (SILAC) and mass spectrometry.  We also 
analyzed the effects of various miRNAs on the expression of FANCD2.  Finally, we 
studied ATR activation in cells stimulated with bortezomib, as well as cell cycle 
regulation by bortezomib in these cells. We show that bortezomib inhibits FANCD2 
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synthesis and overcomes melphalan-induced S-phase arrest, likely via inhibiton of ATR 
activity.  
 Overall, the results presented in this dissertation show that drug response and 
resistance in MM, and possibly other cancers, is mediated by the FA/BRCA DNA 
damage repair pathway.  Therefore, we believe that targeting the FA/BRCA pathway to 
inhibit DNA damage repair, either directly or via inhibition of NF-B, is vital for 
reversing, or possibly circumventing, drug resistance in cancers such as multiple 
myeloma.         
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MATERIALS & METHODS 
 
Cell Culture 
 The 8226 and U266 human multiple myeloma cell lines were obtained from the 
American Type Culture Collection (Manassas, VA), and the corresponding melphalan-
resistant cells (i.e., 8226/LR5, 8226/Dox40, 8226/MR20 and U266/LR6) were generated 
in our laboratory as previously described (38, 177-179).  All cell lines were maintained in 
RPMI 1640 (GIBCO, Carlsbad, CA) supplemented with 5% FBS (Omega Scientific, 
Tarzana, CA), 1% penicillin/streptomycin, and 100 mM L-glutamine (Invitrogen, 
Carlsbad, CA).  The 8226/LR5 and U266/LR6 melphalan resistant cells were passaged 
weekly in medium containing 5 M or 6 M melphalan (Sigma-Aldrich, St. Louis, MO), 
respectively.  The 8226/Dox40 cell line was maintained in 40 M doxorubicin (Sigma-
Aldrich), and the 8226/MR20 line was passaged weekly in 20 M mitoxantrone (Sigma-
Aldrich).  All cell lines are routinely tested (every three months) for mycoplama 
contamination and kappa/lambda expression.  
 
Cytotoxicity Assays 
  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis 
was used to compare levels of sensitivity to melphalan in the absence or presence of 
bortezomib (Millennium Pharmaceuticals, Cambridge, MA).  8226/S, 8226/LR6, U266/S 
and U266/LR6 cells were seeded at 20,000-25,000 cells/well in a 96-well plate.  These 
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cells were pre-treated for 8 hours with 3x10
-9
 M bortezomib or vehicle control, followed 
by a 40 hour treatment with 2-fold serial dilutions of melphalan, ranging from 2x10
-4
 M 
to 6.3x10
-6
 M.  Cells were maintained at 37°C, 5% CO2 for a total of 48 hours before 
harvesting.  50 l of MTT dye (2 mg/ml in PBS; Sigma-Aldrich) was added to each well 
and the cells were incubated at 37°C for an additional four hours.  Plates were then 
centrifuged, media aspirated, and formazan was solubilized by adding 100 l DMSO.  
Optical density was measured at 540 nm using a Dynex II plate reader (Dynex 
Technologies, Chantilly, VA).  The control used to normalize the bortezomib plus 
melphalan samples was bortezomib treatment alone.  Three independent experiments 
were performed.  IC50 values were solved for using a probit model (PROC PROBIT in 
SAS software), and a paired t-test was then utilized to test for a significant difference 
between the IC50 values in the melphalan-treated versus combination bortezomib plus 
melphalan-treated groups.   
  MTT analysis was also used to analyze growth inhibition of the 8226/S and 
8226/LR5 cell lines following treatment with BMS-345541 (Calbiochem, Gibbstown, 
NJ).  Cells were seeded at 8,000-10,000 cells per well and treated with 1-5 M BMS-
345541 for a period of 96 hours.  Following incubation with drug, cells were analyzed as 
described in the previous paragraph.  
 
mRNA Isolation and qPCR Analysis 
 Quantitative RT-PCR was used to analyze FA/BRCA pathway mRNA expression 
in 8226 and U266 cells following drug treatment.  Specifically, 8226/S and 8226/LR5 
cells were treated with 10 nM bortezomib.  Samples were collected and analyzed at 2, 4, 
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8, and 24 hours post-bortezomib.  For the combination bortezomib plus melphalan 
studies, 8226/LR5 cells were pre-treated with 3 nM bortezomib for eight hours followed 
by 16 hours treatment with 25 M melphalan.  In a different study, 8226/S, 8226/LR5, 
U266/S and U266/LR6 cells were treated with 4 M BMS-345541 and analyzed at 2, 4, 
8, 12, 16 and 24 hours post-drug treatment.   
 Following drug treatment, total RNA was extracted using the RNeasy Micro kit 
(Qiagen, Valencia, CA) and, subsequently, cDNA was synthesized using the SuperScript 
First Strand Synthesis kit (Invitrogen), according to the manufacturers‟ instructions.  
Quantitative RT-PCR was then carried out using either a customized microfluidic card 
(Applied Biosystems, Foster City, CA) or an Assay on Demand probe (Applied 
Biosystems), with the ABI 7900 Sequence Detection System (Applied Biosystems).  
Results were analyzed using the comparative CT method of analysis and SDS 2.1 
software (Applied Biosystems). All samples were standardized to the endogenous control 
gene gapdh, and externally normalized to the corresponding vehicle control sample. 
 Initially, a customized microfluidic card was used to simultaneously analyze the 
expression of 11 FA/BRCA pathway-related genes, brca1, brca2, fanca, fancc, fancd2, 
fance, fancf, fancg, fancl, rad51, and rad51c, in 8226 cells treated with either 10 nM 
bortezomib or 4 M BMS-345541.  In order to incorporate recent additions to the 
FA/BRCA family, later studies were performed using a customized card that allowed for 
the analysis of 15 FA/BRCA-related genes, brca1, brca2, fanca, fancb, fancc, fancd2, 
fance, fancf, fancg, fanci, fancj, fancl, fancm, fancn, and usp1.  This updated card was 
used to analyze the effect of BMS-345541 treatment on U266 cells.  Finally, fancd2 gene 
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expression was determined using the fancd2 20X Assay on Demand probe for the 
combination bortezomib plus melphalan studies.  
 The effect of BMS-345541 and bortezomib on FA/BRCA gene expression was 
statistically analyzed by determining whether relative change of gene expression deviated 
from 1 for each cell line (e.g., 8226/S, 8226/LR5, U266, and U266/LR6).  A relative 
change less than 1 indicates downregulation of mRNA expression compared to the 
vehicle control.  Since each gene showed a non-linear pattern of relative change over 
time (see Figures 2, 19 and 21), instead of using a linear slope for testing, a linear model 
with time as a categorical explanatory variable was used to test the null hypothesis of fold 
change=1 at each time point.  Also, since multiple genes related to the FA/BRCA 
pathway were tested simultaneously, the p-value was adjusted based on the false 
discovery rate to control for simultaneous testing (180). 
 
Western Blot Analysis 
 Immunoblot analysis was used to analyze FANCD2 and NF-B family protein 
expression in 8226/S, 8226/LR5, U266/S and U266/LR6 cells following drug treatment.  
To analyze the effect of bortezomib on FANCD2 expression, 8226/LR5 and U266/LR6 
cells were pre-treated with 3 nM bortezomib or vehicle control for eight hours and 
subsequently stimulated with melphalan or vehicle control for 16 hours (24 hours drug 
treatment total).  Following stimulation with drug, cells were washed twice in ice cold 
PBS and cell extracts were prepared by resuspending in high-salt lysis buffer (50 mM 
Tris-HCl [pH 7.4], 1 M NaCl, 0.1% NP-40, 1 mM dithiothreitol) supplemented with 1 
Complete, Mini protease inhibitor cocktail tablet (Roche Applied Science, Indianapolis, 
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IN), 25 mM NaF, 2 mM sodium orthovanadate, and 0.1 M NaP2O4, per 10 mL lysis 
buffer.  Samples were then sonicated, incubated on ice for 30 min, and lysates were 
quantified with Bio-Rad reagent (Bio-Rad, Hercules, CA).  25 g lysate was separated 
using a 3% to 8% NuPage gel (Invitrogen) and transferred to Protran nitrocellulose 
membrane (Whatman, Dusseldorf, Germany).  FANCD2 protein levels were examined 
using an -FANCD2 antibody (1:5000; Novus Biologicals, Littleton, CO), which detects 
both non- and mono-ubiquitinated FANCD2.   Equal loading was determined by probing 
for the housekeeping protein -actin (1:10,000; Sigma).  Membranes were visualized 
using Western Lightning Plus-ECL chemiluminescence substrate (Perkin-Elmer, 
Waltham, MA). 
 IKK phosphorylation was also examined in 8226/S and 8226/LR5 cells following 
stimulation with 25 and 50 M melphalan, respectively, for 5-120 minutes.  Proteins 
were lysed and analyzed as described above, and -phospho-IKK/IKK (1:100, Cell 
Signaling, Danvers, MA), -IKK (1:500; Cell Signaling), -IKK (1250; Cell 
Signaling), and --actin antibodies were used.  The phospho-IKK/IKK antibody 
specifically recognizes IKK and IKK after phosphorylation at Ser-176/Ser-180 and 
Ser-177/Ser-181, respectively.  Finally, following siRNA transfection of various NF-B 
subunits, protein expression was analyzed using -FANCD2, -p65 (1:1500), -p50 
1:1000), -c-Rel (1:200), -RelB( 1:500), and -p52 (1:1000) (Santa Cruz 
Biotechnology) antibodies.  TRAF2 (1:500; Imgenex, San Diego, CA) and FLIPL (1:200; 
BD Biosciences, San Jose, CA) antibodies were used as positive controls, and GAPDH 
(1:500; Cell Signaling) served as the negative control in these experiments. 
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Immunofluorescent Microscopy 
 Immunofluorescence techniques were used to analyze nuclear FANCD2 foci 
formation.  Cells were treated with either vehicle control or bortezomib for 8 hours, 
followed by 5 hours treatment with melphalan. A cytospin was performed using 60,000 
cells/slide, followed by fixation with 2% paraformaldehyde (Sigma-Aldrich). Slides were 
washed twice in PBS and cells were permeabilized using 0.3% Triton X-100 in PBS 
supplemented with 1% normal goat serum (NGS; Sigma).  Following permeabilization, 
cells were blocked for 30 minutes with 5% NGS, 0.1% Triton X-100 in PBS. Slides were 
then stained with -FANCD2 antibody (1:1000) for 2 hours in a humidified chamber.  
Next, samples were washed three times in PBS and incubated for one hour with Alexa 
Fluor 488 secondary antibody (1:1000; Molecular Probes, Invitrogen).  Finally, samples 
were washed three times in PBS and a coverslip was mounted on each slide using 
VECTASHIELD Hardset Mounting Medium containing 4‟, 6‟-diamidino-2-phenylindole 
(DAPI; Vector Labs, Burlingame, CA).  Fluorescence was detected using the Zeiss 
Axiovert Upright Fluorescent Microscope, and 100 cells per condition (control; 
melphalan; bortezomib; and bortezomib plus melphalan) were scored as having greater or 
less than 5 foci.  Three independent experiments were performed and Tukey‟s method of 
statistical analysis was employed to compare differences between the four different 
groups.   
 
Comet Assay 
  DNA damage was assessed using the Alkaline Comet Assay as previously 
described (4).  8226/LR5 cells were either pre-treated with 3 nM bortezomib or control 
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for 8 hours followed by 5 hours treatment with 25 M melphalan. 8226/LR5 cells were 
also transfected with FANCD2 or control siRNA duplexes and, 48 h later, the cells were 
exposed to various amounts of 25 M melphalan or vehicle control for 5 h.  Following 
drug treatment, samples were irradiated at 9 Gy to induce single strand breaks (MARK I 
model 68A irradiator; J.L. Shepherd and Associates, San Fernando, CA).  5,000 cells 
were then washed once in PBS at 4C, and 1% agarose was added to each sample.  The 
agarose/cell suspension was loaded onto a frosted glass microscope slide and allowed to 
solidify.  The slides were then placed in ice cold lysis buffer (2.5 M NaCl, 10 mM 
EDTA, 1% sodium sarcosinate, 1% Triton X-100, 10% DMSO, and 10 mM Tris; pH 
10.0) for 1 hour at 4C.  Following lysis, slides were washed for 1 hour in alkaline wash 
buffer (0.03 M NaOH, 1 mM EDTA; pH 12.2).  The samples were then electrophoresed 
for 20 minutes at 25 V and re-equilibrated with TBE.  The DNA was stained with SYBR 
Green (1:10,000; Molecular Probes, Eugene OR) and slides were washed twice in TBE.  
50 random images per slide were captured using fluorescent microscopy and quantified 
using Loats Associates comet analysis software (Loats Associates, Inc., Westminster, 
MD).  The percent cross-linking was calculated using the equation:  % cross-linking = 1 - 
[(value-mean controlno IR)/(mean controlIR – mean controlno IR)].  The control used for the 
bortezomib plus melphalan studies was bortezomib treatment alone.  A hierarchical linear 
model was fit, with condition (melphalan or melphalan plus bortezomib) as a fixed effect, 
and independent experiment as a random effect, to analyze the results of three 
independent experiments.  (Confirmatory analyses were also performed without including 
the experiment effect).  Mean percentage interstrand crosslinks (% ICLs) and 95% 
confidence intervals were generated.  Analyses were performed in SAS, PROC MIXED. 
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 To examine the effect of the loss of RelB/p50 on re-sensitization of 8226/LR5, 
cells were co-transfected with RelB and p50 siRNAs or siRNA control duplexes for 48 
hours, followed by stimulation with 25-100 M melphalan for five hours and irradiated 
and processed as described above.  A linear regression was used to compare differences 
in melphalan-induced ICL formation in 8226/S and 8226/LR5 siRNA-transfected cells 
(i.e., LR5 RelB/p50 and LR5 siControl) relative to the 8226/LR5 wild-type cell line. 
 
Patient Sample Plasma Cell Isolation and Purification 
 FA/BRCA pathway mRNA expression was analyzed in myeloma cells purified 
from patients enrolled in an Institutional Review Board approved clinical trial for patients 
with primary refractory myeloma, after obtaining informed patient consent.  As per 
protocol, patients were treated with 1.3 mg/m
2
 bortezomib on days 1, 4, 8, and 11, every 
three weeks for two cycles. Following completion of the bortezomib cycles, patients 
underwent high-dose melphalan treatment immediately followed by one dose of 
bortezomib as a conditioning regimen for tandem autologous peripheral blood stem cell 
transplants. Samples were collected and analyzed from three patients at the time of 
screening (baseline controls) and at 24 h after receiving the day 1 of cycle #1 bortezomib 
dose.  Samples analyzed from a fourth patient were collected at screening, after 1 dose of 
bortezomib, after 2 cycles of bortezomib, three months post-transplant, and at relapse.  
 Plasma cells were isolated using a negative selection protocol, providing for 
>95% purity.  Briefly, 1 mL of bone marrow aspirate was centrifuged in a Ficoll-Plaque 
Plus gradient (Amersham Biosciences, Piscataway, NJ), and a cytospin of the isolated 
cells was used to determine the initial purity of the plasma cell population.  In parallel, 10 
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mL of the bone marrow sample was incubated with Millennium‟s Rosette Antibody 
Cocktail (Millennium Pharmaceuticals) for 20 minutes, followed by Ficoll extraction. To 
assess the efficiency of selection, a new cytospin was prepared from these cells.  Once 
the myeloma cells were isolated, RNA was extracted, cDNA synthesized, and q-PCR 
analysis of FA/BRCA-related mRNA expression was performed as described above. 
 
Promoter Region Analysis 
 Putative transcription factor binding sites on the promoter regions of  brca1, 
brca2, fanca, fancb, fancc, fancd2, fance, fancf, fancg, fanci, fancj, fancl, fancm, and 
fancn (-3000 to +1 segments of the genomic sequences) were detected using a public 
version of „P-Match‟ (http://www.gene-regulation.com/cgi-
bin/pub/programs/pmatch/bin/p-match.cgi) and the database provided by TRANSFAC 
(http://www.gene-regulation.com/pub/databases.html).  Matrix-scores (>0.990) were 
determined using 3 sets of optimized cut-off values. 
 
Electrophoretic Mobility Shift Assays 
  NF-B DNA binding activity was assessed utilizing the electrophoretic mobility 
shift assay (EMSA).  Nuclear extracts were prepared from 8226 and U266 cells, and 
EMSAs were carried out as described previously (ref). For gel shifts, nuclear extracts 
were incubated on ice with NF-B-specific antibodies for 30 min prior to EMSA 
analysis.  
 NF-B DNA binding activity was measured using a probe containing the well-
described sequence of the B enhancer, 5‟-TAGTTGAGGGGACTTTCCCAG-3‟. When 
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indicated, nuclear extracts were incubated with the following oligonucleotides containing 
FANCD2-specific consensus NF-B binding sites: 5‟-
TTCAGACAGGGGCTCTCCCATTGCAA-3‟ (Probe I); 5‟-
TTTCCCCAGGAAACCCCAATTTGCAA-3‟ (Probe II); 5‟-
TTAATATACTAAAAAACCCTGAATAA-3‟ (Probe III); and, 5‟-
TTTGAAGTGGGGCTTCCCAGACTGAA-3‟ (Probe IV).  As a control for loading, NF-
1 DNA binding activity was measured using a probe derived from the adenovirus-2 
origin of replication (5‟-CTTATTTTGGATTGAAGCCAATAT-3‟).  Klenow (exo-) 
(New England Biolabs, Ipswich, MA) was added to the samples in the presence of 
[32P]ATP for 30 minutes at 37C.  A gel filtration column (Roche, Basel, Switzerland) 
was used to remove unincorporated nucleotide, and 20-40 kcpm of probe was incubated 
with 5 g protein extract plus 1g poly dI:dC for 20 minutes at room temperature. 
Protein-DNA complexes were resolved on a 5% nondenaturating polyacrylamide gel and 
detected by autoradiography. 
 
Combination Index Analysis 
 As a means to determine if bortezomib and BMS-345541 exact their cytotoxic 
effects by altering the same pathway (ie – NF-B), the dose-effect relationship between 
these two drugs was analyzed in the 8226/LR5 and U266/LR6 cell lines.  Cells were 
seeded at 15,000 cells per well and drugs were added both alone and in combination, 
simultaneously for a total of 72 hours.  The concentration of bortezomib added to the 
8226/LR5 cell line varied from 3-10.5 nM, and from 2-5.3 nM in the U266/LR6 cell line. 
BMS-345541 was added to the 8226/LR5 and U266/LR6 cells at a range of 
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concentrations from 500-1750 nM and 1500-4000 nM, respectively.  The drugs were 
added at a constant molar ratio (1:167 for the 8226/LR5 cell line and 1:750 for the 
U266/LR6 cells).  Following 72 hours incubation with drug, MTT dye was added and 
samples were processed as described above.  Percent survival was determined relative to 
vehicle control-treated samples.  The dose-effect relationship was analyzed using 
CalcuSyn software (Biosoft, Ferguson, MO), and is based on the Chou-Talalay multiple 
drug effect equation (181).  A combination index value equal to 1 indicates that the two 
drugs are additive, >1 indicates synergism, and <1 denotes antagonism.  Three 
independent experiments were performed.          
 
Transfection of siRNA, plasmids, and miRNA 
 8226 cells were seeded in complete medium at a concentration of 2  105 cells/ml. 
After 24 hours, 4-5  106 cells/sample were resuspended in 200 l of cytomix buffer 
(containing 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4, 25 mM Hepes, 2 
mM EGTA, 5 mM MgCl2, 2 mM ATP, and 5 mM glutathione [pH 7.6]), mixed with the 
indicated „ON-TARGET plus‟ siRNA duplexes (Dharmacon, Lafayette, CO) at a final 
concentration of 67 nM, and electroporated at 140 V/975 F using the Bio-Rad 
GenePulser XCell (Bio-Rad, Hercules, CA).  A similar transfection protocol was used for 
the overexpression of untagged, full-length FANCD2 using pIRES-neo-FANCD2 (exon 
44 variant; 20 g) plasmid DNA. 
 The following siRNA sequences were used (target mRNAs in parentheses): 5‟-
UGGUUUACAUGUCGACUAA-3‟, 5‟-UGGUUUACAUGUUGUGUGA-3‟, 5‟-
UGGUUUACAUGUUUUCUGA-3‟, and 5‟-UGGUUUACAUGUUUUCCUA-3‟ 
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(siControl, Non-Targeting pool); 5‟-CGUACGCGGAAUACUUCGA -3‟ (Luciferase); 
5‟-GUGCCAGGAUCACGUAGAAUU-3‟ (c-Rel); 5‟-
CGAACAGCCUUGCAUCUAGUU-3‟ (p52); 5‟-GGAUUGAGGAGAAACGUAAUU-
3‟ (p65); 5‟-CUGCGGAUUUGCCGAAUUAUU-3‟ (RelB); 5‟-
GGAGACAUCCUUCCGCAAAUU-3‟ (p50); and, 5‟-UGGAUAAGUUGUCGUCUAU-
3‟, 5‟-CAACAUACCUCGACUCAUU-3‟, 5‟-GGAUUUACCUGUGAUAAUA-3‟, 5‟-
GGAGAUUGAUGGUCUACUA-3‟ (FANCD2 Targeting pool).  Transfected cells were 
typically used in experiments 24-48 hours post-transfection. 
 The effects of hsa-miR-16, has-miR-23a, and hsa-miR-27 on FANCD2 
expression were also analyzed in the 8226/LR5 cell line.  The same transfection protocol 
as described above was used to transfect cells with pre- or anti-miRNAs at a 
concentration of 50 nM.  Samples were collected at 24, 48 and 72 hours post-transfection. 
 
Chromatin Immunoprecipitation Assays 
 8226/S and 8226/LR5 cells were cross-linked in formaldehyde (20  106 
cells/sample), lysed in SDS-rich buffer, and the resulting nuclear fractions were sonicated 
until the average chromatin size reached 200-1000 bp (~2-4, 10 sec pulses/sample). The 
cell extracts were pre-cleared with heat-inactivated, protein A-coated Staphylococcus 
aureus cells (PANSORBIN cells, Calbiochem), and were immunoprecipitated with 
normal rabbit IgG or -NF-B/Rel specific antibodies. After three washes, DNA/protein 
cross-links were reversed at 65C; and, a close-to-pure fraction of DNA was obtained 
with a ChIP-IT mini-column (Active Motif) and analyzed by quantitative PCR. 
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 The ChIP DNA was subjected to quantitative RT-PCR using the following primer 
pairs: 5‟-AATGAATGGGCAGCCGTTA-3‟ and 5‟-TAGCCTCGCTCCACCTGACT-3‟ 
(GAPDH, control samples); 5‟-GGGTCTGCAGGAGATCAACTAAGAAA-3‟ and 5‟-
GTGCCTGGCCCTATGCTGTAACTA-3‟ (FANCD2, STATx); and, 5‟-
GAGCCAAGAGGTACCCTGATAAAGTC-3‟ and 5‟-
CAGCTTTGGTTTAATACCTGTCAGAATT-3‟ (FANCD2, NF-B).  
 
Diffusion Apoptosis Slide Halo (DASH) Assay 
 Apoptosis was analyzed using the DASH Assay kit (Trevigen, Helgerman, CT), 
which detects DNA fragmentation.  This assay captures and detects damage-induced low 
molecular-weight DNA fragments as diffuse halos in an agarose microgel.  After the 
indicated siRNA transfections, the cells were treated with 25-100 M melphalan or 
vehicle control for 24 hours, then washed with PBS and embedded in low melting 
agarose. The embedded cells were lysed for 10 minutes under alkaline conditions, and 
DNA was precipitated and visualized with SYBR Green fluorogenic dye.  Fifty images 
were randomly captured per slide, and the logarithmic radius of each nucleoid was 
calculated using the tail-length parameter of the Loats Associates comet analysis 
software. 
 Analysis of variance (ANOVA) was employed to test whether nuclear DNA 
diffusion after melphalan treatment was different among all experimental groups. The 
Tukey‟s Honest Significance Difference method was used to adjust P-values for multiple 
comparisons (182). To examine the relationship between the nuclear DNA diffusion and 
ICL, Pearson correlation was used to study their association (183). 
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Stable Isotopic Labeling of Amino Acids in Cell Culture 
FANCD2 protein half-life and doubling time was analyzed via stable isotopic 
labeling of amino acids in cell culture (SILAC).  8226/LR5 cells were cultured for six 
doublings (approximately seven days) in “heavy media” (RPMI 1640 deficient in lysine, 
arginine, glutamine, and phenol red, and supplemented with 5% dialyzed FBS, 1% 
penicillin/streptomycin, 100 mM L-glutamine, [U-
13
C6]-L-Lysine HCl and [U-
13
C6, 
15
N4]-L-Arginine).  Following isotopic labeling, cells were washed twice in PBS and re-
suspended in “light media” (RPMI 1640 routinely used for cell culture).  Cells were 
divided into two flasks, 3 nM bortezomib or vehicle control was immediately added, and 
samples were harvested at 0, 4, 8, 12, 24 and 36 hours.  Labeling with heavy media 
followed by a chase with light media allows for the simultaneous analysis of FANCD2 
degradation (decrease in isotopically labeled FANCD2) and FANCD2 synthesis 
(incorporation of light/normal amino acids).   
Samples were harvested in high salt lysis buffer (50 mM Tris-HCl pH7.4, 0.1% 
NP-40, 1M NaCl, protease inhibitor cocktail (Roche), 25 mM NaF, 2 mM Na3VO4, and 
0.1 M Na2HPO4), sonicated, and centrifuged at 14,000 rpm for 10 minutes.  Aliquots of 
the cell lysate (equivalent to 300,000 cells) were denatured by boiling in loading buffer 
and separated by 4-12 % Criterion XT Bis-Tris gels for 80 minutes at 150 V. The gel was 
stained with colloidal Coomassie Brilliant
 
Blue G-250 (Bio-Rad).  Bands from the mass 
of interest were excised and destained with 50% MeOH and 50 mM ammonium 
bicarbonate.  Samples were then reduced with 2 mM tris (2-carboxyethyl) phosphine, 
alkylated with 20 mM iodoacetamide, and digested with trypsin (Promega, Madison, WI) 
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overnight at 37ºC. Following digestion, peptides were extracted and concentrated under 
vacuum centrifugation. 
Using a Proxeon nanoLC system, the sample (~150,000 cells) was loaded onto a 
trap column (300 μm x 5 mm), washed for 20 min, then eluted onto a C18 PepMap 100 
column (LC packings/Dionex, Sunnyvale, CA) with 75 µm inner diameter, 3 µm particle 
size, and 100 Å pore size. Peptides were eluted on a 35 minute gradient from 5% B to 
50% B over 35 minutes at a flow rate of 300 nl/min.  The solvent system was composed 
of aqueous 2% acetonitrile with 0.1% formic acid (A) and aqueous 90% acetonitrile with 
0.1% formic acid (B).   Peptide precursors were selected in the first quadrupole with a 
mass window of 0.2 (Q1); fragments were filtered at a resolution of 0.7 (Q3).  The scan 
width was set to 0.002, and 15 milliseconds of acquisition time was used per transition.  
Collision energy values were calculated using the equation:  CE = (0.034 * m/z) + 3.314 
V, based on the mass-to-charge ratio of the doubly charged peptide precursor. 
Peak areas were identified and calculated using MRMer, which has been 
implemented as a pipeline in GenePattern (184).  The raw data files from the instrument 
are converted into mzxml format; then, the LC-MRM peaks are extracted and visualized 
for data evaluation.  Resulting files were then compared using Post MRMer, developed in 
house for data visualization and evaluation, as well as comparison of sample groups. 
MRM was performed on a Finnigan TSQ Quantum triple quadrupole mass spectrometer 
(Thermo Finnigan, San Jose, CA). The internal standard DAFFGNPR was added at a 
concentration of 20 fmole/injection to the samples after in-gel digestion and was used as 
a normalization constant. 
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BrdU/PI Cell Cycle Analysis 
 8226/LR5 cells were pre-treated with 3 nM bortezomib for eight hours and 
subsequently treated with 25 M melphalan.  1x106 cells were incubated with 30 g/ml 
bromodeoxyuridine (BrdU) for 30 minutes after 8, 24, 36, and 48 hours drug treatment.  
Samples were then washed once in cold PBS and fixed overnight at 4°C with 4 ml cold 
PBS plus 6 ml cold 100% EtOH.  Next, samples were centrifuged and 4 ml Pepsin 
solution (0.04% pepsin, 0.1% HCl) was added.  Samples incubated while shaking for 1 
hour at 37°C.  The DNA was then denatured by the addition of 2 N HCl for 30 minutes at 
37°C, followed by washing once with 0.1 M sodium borate to neutralize the acid.  
Samples were then washed once in PBTB (0.5% Tween-20, 0.5% BSA in PBS), and 
incubated in the dark for one hour with 10 l FITC-conjugated anti-BrdU in 200 l 
PBTB.  Next, samples were centrifuged and incubated with 200 l PBTB containing 10 
g/ml propidium iodide and 0.25 mg RNase A for 30 minutes at 37°C.  Finally, samples 
were centrifuged, re-suspended in 400 l PBS, and analyzed using a FACScan flow 
cytometer (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR). 
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RESULTS 
 
Part I: 
Fanconi Anemia/BRCA Pathway Expression in Drug Resistant Cell Lines 
 Our lab was the first to report that members of the FA/BRCA DNA damage repair 
pathway are overexpressed in melphalan resistant myeloma cell lines (3-4).  Furthermore, 
inhibition of FANCF in the melphalan resistant 8226/LR5 cell line partially reversed 
resistance in these cells, and FANCF overexpression in the drug sensitive cells conferred 
resistance to melphalan (3).  Furthermore, members of the FA/BRCA pathway have been 
shown to mediate sensitivity to cisplatin, BCNU, and TMZ in different tumor types as 
well (170, 172-175).  Based on these reports, we hypothesized that overexpression of 
FA/BRCA pathway members is a common mechanism by which tumor cells acquire 
resistance to chemotherapeutic agents.  This section of the dissertation summarizes our 
findings regarding FA/BRCA pathway mRNA expression in isogenic drug sensitive and 
drug resistant tumor cell lines.  We found that cells selected for resistance to the 
alkylating agents melphalan and cisplatin overexpress FA/BRCA pathway genes, 
whereas cells selected for resistance to topoisomerase II inhibitors specifically 
overexpress FANCF.  
 
FA/BRCA Pathway mRNA is Overexpressed in Cells Selected for Resistance to 
Melphalan and Cisplatin 
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 The DU-145/M4.5 prostate cancer cell line was selected for resistance to 
melphalan by chronically treating the parental DU-145 cell line with low doses of 
melphalan for a period of three years (185).  The DU-145/M4.5 cells are approximately 
27-fold resistant to melphalan when compared to the drug sensitive parental cells (185).  
Quantitative-RT-PCR analysis of FA/BRCA pathway mRNA expression was performed 
in these cell lines using a customized microfluidic card to analyze expression of 11 
FA/BRCA pathway related genes (brca1, brca2, fanca, fancc, fancd2, fance, fancf, fancg, 
fancl, rad51 and rad51c).  Similar to our published results showing overexpression of 
FA/BRCA pathway genes in melphalan resistant myeloma cell lines (3-4), the DU-
145/M4.5 melphalan resistant prostate cancer cell line shows enhanced FA/BRCA 
pathway expression when compared to the drug sensitive parent cell line (Figure 4A).  
Specifically, nine of 11 genes analyzed (brca1, brca2, fanca, fancc, fancd2, fance, fancg, 
rad51 and rad51c) show at least two-fold enhanced expression in the melphalan resistant 
versus melphalan sensitive cells.   
 We next analyzed FA/BRCA pathway mRNA expression in cells selected for 
resistance to cisplatin, another alkylating agent.  The C13* ovarian cancer cell line was 
selected for resistance to cisplatin (186).  This cell line is approximately 15-fold resistant 
to cisplatin when compared to the drug sensitive OV2008 cell line, and is also cross-
resistant to melphalan (186).  Analysis of FA/BRCA pathway mRNA expression revealed 
overexpression of many of these genes, similar to the results seen in cells selected for 
resistance to melphalan (Figure 4B).  Based on these results, we conclude that selecting 
tumor cells for resistance to alkylating agents typically results in overexpression of  
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Figure 4.  Melphalan and cisplatin resistant cells overexpress FA/BRCA pathway 
genes.  mRNA levels of FA/BRCA pathway genes were analyzed in melphalan and 
cisplatin resistant cell lines using a customized microfluidic card and q-PCR analysis.  
(A) The DU-145/M4.5 prostate cancer cell line is ~27-fold resistant to melphalan when 
compared to the drug sensitive DU-145 parental cell line.  n=1.  (B) C13* cells are ~15–
fold resistant to cisplatin when compared to the drug sensitive OV2008 parental cell line.  
n=3.   
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members of the FA/BRCA pathway, and targeting this pathway is likely vital for 
overcoming drug resistance.   
 
FANCF is Specifically Overexpressed in Myeloma Cells Selected for Resistance to 
Topoisomerase II Inhibitors 
 We next analyzed FA/BRCA pathway mRNA expression in myeloma cells 
selected for resistance to doxorubicin and mitoxantrone.  These two chemotherapeutic 
agents are classified as topoisomerase II inhibitors, which function by inhibiting this 
enzyme, resulting in single and double strand breaks.  The 8226/Dox40 cell line was 
selected for resistance to doxorubicin via chronic stimulation with increasing doses of 
this drug for a period of 10 months, and these cells are approximately 10-fold resistant to 
doxorubicin when compared to the drug sensitive 8226/S parent cell line (178).  Unlike 
cells selected for resistance to alkylating agents, the doxorubicin resistant myeloma cells 
do not show global enhanced expression of FA/BRCA pathway genes (Figure 5A).  
These cells do, however, specifically overexpress FANCF. 
 FA/BRCA pathway mRNA expression was next analyzed in the mitoxantrone 
resistant 8226/MR20 cell line.  When compared to the drug sensitive parent cell line, 
these cells are close to 40-fold resistant to mitoxantrone.  Interestingly, similar to the 
results seen with the 8226/Dox40 cells, the 8226/MR20 cells show enhanced expression 
of FANCF (Figure 5B).     
 Collectively, the results presented in this section of the dissertation show 
enhanced mRNA expression of many FA/BRCA pathway members in tumor cells  
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Figure 5.  Doxorubicin and mitoxantrone resistant myeloma cells overexpress FANCF.  
mRNA levels of FA/BRCA pathway genes were analyzed in doxorubicin and mitoxantrone 
resistant myeloma cell lines using a customized microfluidic card and q-PCR analysis.  (A) The 
8226/Dox40 cell line is ~10-fold resistant to doxorubicin when compared to the drug sensitive 
8226/S parental cell line.  n=3.  (B) 8226/MR20 cells are ~37–fold resistant to mitoxantrone 
when compared to the drug sensitive 8226/S parental cell line.  n=3.   
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selected for resistance to melphalan or cisplatin, whereas cells selected for resistance to 
topoisomerase II inhibitors specifically overexpress FANCF.  
 
Part II: 
Bortezomib Enhances Melphalan Response in Multiple Myeloma Cell Lines and 
Patient Samples 
 Although there are many options available today for the treatment of multiple 
myeloma (MM) that did not exist even ten years ago, this disease remains incurable, 
mainly due to the emergence of drug resistance following chemotherapy.  Our laboratory 
previously reported that members of the FA/BRCA pathway are overexpressed in 
melphalan resistant cell lines, and causative for this resistance (3-4).  Specifically, using 
siRNA techniques to inhibit FANCF expression in the melphalan resistant 8226/LR5 cell 
line partially reversed resistance (3).  Conversely, overexpression of FANCF in the drug 
sensitive 8226/S cell line conferred resistance to melphalan (3).  Based on these results, 
we hypothesized that bortezomib enhances melphalan response by inhibiting FA/BRCA 
pathway expression.  
 Current MM treatment regimens include combining different agents to 
circumvent or overcome drug resistance.  Others have reported that the proteasome 
inhibitor bortezomib enhances melphalan response in vitro (59, 78), as well as in clinical 
trials (25, 27-28, 79).  However, the mechanism by which this enhanced response occurs 
remains unclear.  Based on our previous reports that the FA/BRCA pathway is involved 
in melphalan resistance, we hypothesized that bortezomib enhances melphalan response 
by inhibiting expression and function of the FA/BRCA DNA damage repair pathway.  
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This hypothesis is further substantiated by a recent report, which found that proteasome 
function is required for FA/BRCA pathway activation (176).  In this portion of the 
dissertation, we analyze the role of the FA/BRCA pathway in enhanced melphalan 
response by bortezomib.  We show that bortezomib inhibits mRNA expression of many 
FA/BRCA pathway members.  We also demonstrate that FANCD2 mRNA and protein 
expression is inhibited, even in the presence of melphalan, and that bortezomib inhibits 
melphalan-induced FANCD2 foci formation.  Bortezomib also enhanced DNA damage 
induced by melphalan treatment, likely via inhibition of FANCD2 expression.  
Importantly, we also show that bortezomib inhibits FA/BRCA pathway expression in 
MM patient specimens.  Combined, these results show that bortezomib enhances 
melphalan response via inhibition of the FA/BRCA pathway, and provide a target for 
overcoming or even circumventing drug resistance in multiple myeloma and possibly 
other cancers.       
 
Bortezomib Enhances Melphalan Response in Myeloma Cell Lines 
 To test our hypothesis that bortezomib enhances melphalan response via 
inhibition of the FA/BRCA pathway, we first needed to confirm the work of others that 
bortezomib does indeed enhance melphalan cytotoxicity.  Since we believed that 
bortezomib enhances melphalan response by inhibiting this pathway, we first treated cells 
with bortezomib, followed by exposure to melphalan.  Using MTT assays, we pre-treated 
two melphalan sensitive cell lines (8226/S and U266/S), and two melphalan resistant cell 
lines (8226/LR5 and U266/LR6), with a non-toxic dose (3nM) of bortezomib for eight 
hours, followed by treatment with varying doses of melphalan for 40 hours (48 hours 
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total drug treatment).  The results show that pre-treatment with bortezomib enhances 
sensitivity to melphalan when compared to melphalan treatment alone (Figure 6).  In all 
four cell lines, statistical analysis of the IC50 values generated from three independent 
experiments revealed a statistically significant reduction in the IC50 values of cells pre-
treated with bortezomib versus cells exposed only to melphalan.  These results confirm 
the work of others and show that pre-treatment with a non-toxic dose of bortezomib 
enhances melphalan response.  
  
Bortezomib Downregulates FA/BRCA Pathway mRNA Expression 
We next wanted to determine if bortezomib inhibits FA/BRCA pathway expression and 
function.  To this end, we analyzed FA/BRCA pathway gene expression in the 8226/S 
and 8226/LR5 cell lines following treatment with 10 nM bortezomib.  Samples were 
collected at 2, 4, 8, and 24 hours, and mRNA expression was analyzed using a 
customized microfluidic card (which allowed for simultaneous analysis of eight FA 
genes, fancd1/ brca2, fanca, fancc, fancd2, fance, fancf, fancg, fancl,and three DNA 
damage response genes, brca1, rad51 and rad51c) and quantitative RT-PCR.  
Bortezomib decreased expression of certain FA/BRCA pathway members in both cell 
lines in as little as 2 hours, with maximal effect seen at 24 hours (Figure 7).  Specifically, 
bortezomib significantly reduced expression of brca2, fancc, fancd2, fance, fancf, fancg, 
fancl, and rad51c in the drug sensitive 8226/S cell line at 24 hours (Table 2).  In the 
8226/LR5 melphalan resistant cell line, fancd2, fance, fancf and fancg were reduced 
significantly following 24 hours treatment with melphalan (Table 2).  Importantly, the 
downregulation of mRNA expression seen following treatment with bortezomib is not  
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Figure 6.  Low-dose bortezomib enhances melphalan response in melphalan sensitive and 
melphalan resistant myeloma cell lines.  Melphalan sensitivity was studied in melphalan 
sensitive and resistant myeloma cell lines in the absence or presence of a non-toxic (3 nM) dose 
of bortezomib.  Percent growth is shown following exposure to melphalan alone or bortezomib 
plus melphalan treatment, in the (A) 8226/S melphalan sensitive and (B) 8226/LR5 melphalan 
resistant cell lines, as well as in the (C) U266/S and (D) U266/LR6 cell line pairs.  The control used 
for the bortezomib plus melphalan studies was bortezomib treatment alone.  At least 3 
independent experiments were performed, and the mean of these experiments and SEM are 
depicted in the growth curve.  Mean IC50 values are also shown. *Statistical significance was 
determined using a paired t-test, and p≤0.02.  Bortezomib enhanced melphalan activity at 
statistically significant levels in all four cell lines.  
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due to a global inhibition of transcription, as expression of genes not related to the 
FA/BRCA pathway (b2m, ipo8 and tfrc) were unaffected by bortezomib treatment 
(Figure 8).  These results suggest that bortezomib may function in part by inhibiting the 
FA/BRCA pathway. 
 
Bortezomib Inhibits FANCD2 mRNA, Protein Expression, and Foci Formation, 
Even in the Presence of Melphalan 
 Of the FA/BRCA pathway-related genes that did change following bortezomib 
treatment, FANCD2 mRNA expression was most consistently and dramatically decreased 
in both the drug sensitive 8226/S and drug resistant 8226/LR5 cell lines.  To further 
characterize the effect of bortezomib on melphalan response, FANCD2 mRNA and 
protein expression was analyzed in the drug resistant 8226/LR5 and U266/LR6 cell lines.  
Cells were pre-treated with either vehicle control or 3 nM bortezomib for eight hours and 
subsequently exposed to 25 M melphalan for 16 hours.  Results showed that melphalan 
treatment alone did not affect FANCD2 mRNA expression in the 8226/LR5 cell line 
whereas bortezomib treatment, both alone and in combination with melphalan, decreased 
expression of FANCD2 (Figure 9A).  Analysis of the U266/LR6 cell line revealed that 
melphalan treatment alone enhanced expression of FANCD2, and, comparable to results 
seen in the 8226/LR5 cell line, bortezomib treatment inhibited FANCD2 gene expression 
(Figure 9B).  Importantly, decreased FANCD2 mRNA expression seen with low-dose 
bortezomib was maintained even in the presence of melphalan in both cell lines.    
 FANCD2 protein expression was also analyzed in the 8226/LR5 and U266/LR6 
cell lines following the same method of treatment with bortezomib, melphalan, or the  
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Figure 7.  Bortezomib downregulates FA/BRCA pathway mRNA expression in 
melphalan sensitive and resistant myeloma cell lines.  8226/S and 8226/LR5 cells 
were treated with 10 nM bortezomib and harvested at indicated times. FA/BRCA gene 
expression was determined in quadruplicate samples by qPCR using a customized 
microfluidic card. Results depict fold change normalized to vehicle control samples.  
Statistical analysis is shown  in Table 2. Three independent experiments were performed.  
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Table 2. Statistical analysis of FA/BRCA gene expression following bortezomib 
treatment  in 8226 cells.  To test the effect of bortezomib on FA/BRCA gene expression 
in 8226/S (A) and 8226/LR5 (B) cells, we examined whether fold change of gene 
expression deviated away from 1. Since each gene showed a non-linear pattern of fold 
change over time (see Figure 2), a linear model with time as a categorical explanatory 
variable was used to test the null hypothesis of fold change=1 at each time point for each 
gene in each cell line. Since we tested 11 FA/BRCA related genes, we adjusted for p 
value based on the false discovery rate to control for simultaneously testing (Benjamini, 
1995).  
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Figure 8. Gene expression levels of B2M, IPO8 and TFRC remain unchanged in 
8226/S cells treated with BMS-345541 and bortezomib. 8226/S cells were treated with 
BMS-345541 or bortezomib as described in Figures 7 and 24.  Relative changes in gene 
expression were obtained by internally standardizing against GAPDH and externally 
standardizing against the control, equal to 1.  Results depict the mean relative change of 
three independent experiments and SEM.  No significant difference in B2M, IPO8 or 
TFRC gene expression was seen following treatment with BMS-345541 or bortezomib.  
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combination (Figure 10).  The antibody against FANCD2 recognizes both non-
ubiquitinated (short, lower band) and monoubiquitinated, activated (long, upper band) 
FANCD2.  Demonstration of the monoubiquitinated form of FANCD2 is evidence for the 
presence and activation of the upstream FA complex (187).  In this study, we found that 
in both cell lines melphalan increased FANCD2 monoubiquitination/activation.  By 
comparison, bortezomib attenuated total FANCD2 protein levels, resulting in a reduced 
amount of monoubiquitinated protein in the cells when compared to basal 
monoubiquitinated FANCD2 levels.  Furthermore, bortezomib effectively reduced 
FANCD2 levels, in the presence or absence of melphalan, compared to melphalan alone.  
These results show that bortezomib impedes FA/BRCA pathway activation by inhibiting 
FANCD2 mRNA and protein expression. 
  To further determine the effects of bortezomib on FANCD2 activation and 
function, immunofluorescent microscopy techniques were used to analyze FANCD2 
DNA repair foci formation, a hallmark of FA pathway activation.  8226/LR5 cells were 
treated with vehicle control or bortezomib for 8 hours, followed by a five hour treatment 
with 50 M melphalan (Figure 11).  FANCD2 foci formation, as measured by percentage 
of cells with greater than five foci, was found to be enhanced following melphalan but 
not bortezomib treatment.  However, melphalan-induced FANCD2 foci formation was 
inhibited when cells were first treated with 3 nM bortezomib.  Tukey‟s method of 
statistical analysis confirmed a difference in foci formation between control and 
melphalan alone; melphalan alone versus bortezomib alone; and melphalan alone versus 
the combination of melphalan and bortezomib.  In contrast, no difference in foci 
formation was seen between the control, bortezomib alone, and the combination of  
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Figure 9.  Bortezomib inhibits FANCD2 mRNA expression, even in the presence of 
melphalan.  8226/LR5 (A) and U266/LR6 (B) cells were pre-treated with 3 nM 
bortezomib followed by 16 hours treatment with melphalan.  Fold changes were obtained 
by internally standardizing against GAPDH and externally standardizing against the 
control, equal to 1 (noted by the solid line).  Three independent experiments were 
performed.  Data shown are mean value and SEM.  *P<0.05.  
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Figure 10.  Bortezomib inhibits FANCD2 protein expression.  Immunoblot analysis of 
8226/LR5 (A) and U266/LR6 (B) cells were pre-treated with 3 nM bortezomib followed 
by 16 hours treatment with melphalan.  Two distinct bands are seen:  the upper, 
monoubiquitinated band and the lower, non-ubiquitinated band.  A representative blot of 
three independent experiments is shown. 
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Figure 11.  Bortezomib inhibits melphalan-induced FANCD2 foci formation.  
Immunofluorescent microscopy was used to detect FANCD2 foci formation.  Melphalan-
induced FANCD2 foci formation was inhibited when cells were pre-treated with 
bortezomib.  Inserts demonstrate the foci typically observed for single cells in respective 
treatment groups.  Three independent experiments were performed.  *Tukey‟s method of 
statistical analysis showed a significant difference between melphalan alone and control; 
melphalan alone and bortezomib alone; and melphalan alone and the combination of 
bortezomib plus melphalan.  No difference was seen between control, bortezomib alone, 
and bortezomib plus melphalan.  
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bortezomib plus melphalan.  Based on these results, we conclude that a non-toxic dose of 
bortezomib inhibits FANCD2 gene expression, FANCD2 protein levels, and FANCD2 
foci formation, even in the presence of melphalan. 
  Previous reports have shown that FANCD2 monoubiquitination and foci 
formation is S-phase specific (156).  Furthermore, others have reported that bortezomib 
can reduce the percentage of cells in S-phase (188-189).  Therefore, we next wanted to 
determine if the reduction of FANCD2 protein expression and foci formation following 
bortezomib treatment was due in part to a lesser number of cells in the S-phase of the cell 
cycle.  In these studies, 8226/LR5 cells were pre-treated with bortezomib for eight hours 
and subsequently exposed to melphalan for 16 hours.  Using BrdU incorporation and PI 
staining, we observed that 3 nM bortezomib treatment does indeed decrease the 
percentage of cells in S-phase, even in the presence of melphalan (Figure 12).  These 
results may in part explain the decrease in total FANCD2 protein expression as well as 
FANCD2 foci formation following bortezomib treatment.   
 
Bortezomib Enhances Melphalan-Induced DNA Damage Via Inhibition of FANCD2 
  Our lab previously reported that DNA interstrand cross-links (ICLs) induced by 
treatment with melphalan were reduced in melphalan resistant cell lines (8226/LR5 and 
U266/LR6) when compared to their respective drug sensitive parent cell lines (8226/S 
and U266/S) (3).  Moreover, DNA damage repair mediated by the FA pathway, as 
indicated by ICL removal, was enhanced in the melphalan resistant cell lines (3-4). Based 
on our previous published results and our present observation that bortezomib reduces 
FANCD2 levels and foci formation, we hypothesized that the amount of DNA damage,  
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Figure 12.  Bortezomib treatment decreases the proportion of cells in S-phase.  
8226/LR5 cells were pre-treated with 3 nM bortezomib followed by treatment with 25 
mM melphalan for 16 hours.  To determine the effect of bortezomib on cell cycle, cells 
were then incubated with BrdU/PI for 30 minutes, fixed, and analyzed using flow 
cytometric techniques.  The mean percentage of cells in each phase of the cell cycle and 
SEM are depicted, based upon three independent experiments.       
 
 
66 
 
as measured by ICLs, would be greater in cells treated with the combination of 
bortezomib plus melphalan as compared to cells treated with melphalan alone.  Using the 
alkaline comet assay, DNA damage was measured in 8226/LR5 cells following treatment 
with 3 nM bortezomib alone, 25 M melphalan alone, or the combination (Figure 13).  
Bortezomib treatment alone did not induce DNA damage when compared to control cells 
(Figure 14).  Melphalan treatment induced DNA damage and DNA interstrand cross-links 
at levels similar to those previously reported by our lab (3).  As predicted, when cells 
were treated with the combination of bortezomib plus melphalan, DNA damage was 
enhanced when compared to cells treated with melphalan alone (Figure 13A).  
  Because bortezomib by itself did not induce DNA damage, the increase in 
damage seen when cells are pre-treated with bortezomib followed by melphalan 
treatment (as compared to melphalan treatment alone) is likely due to reduced DNA 
damage repair.  To determine if inhibition of the FA/BRCA pathway, and in particular 
FANCD2, could result in enhanced DNA damage, we used siRNA to specifically inhibit  
expression of FANCD2.  8226/LR5 cells were transfected with either a control siRNA 
(siControl) or siRNA targeting FANCD2 (siFANCD2).  Following transfection, cells 
were treated with 25 M melphalan for 5 hours, and alkaline comet assays were 
performed.  As shown in Figure 13B, siRNA-mediated inhibition of FANCD2 increased 
the percentage of melphalan-induced ICLs when compared to the control cells.  
Interestingly, similar differences in percentage of ICL formation are observed when 
comparing bortezomib plus melphalan or siFANCD2 plus melphalan to their respective 
controls.  This observation underscores the role of FANCD2 inhibition in the ability of 
bortezomib to enhance melphalan-induced DNA damage.  Taken together, these results  
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Figure 13.  Bortezomib enhances melphalan-induced DNA damage.  The alkaline 
comet assay was used to assess DNA damage.  (A) 8226/LR5 cells were pre-treated with 
borteozmib for eight hours followed by five hours treatment with 25 mM melphalan.  (B) 
FANCD2 expression was inhibited in 8226/LR5 cells using siRNA techniques.  These 
cells were then treated with 25 mM melphalan for five hours and DNA damage was 
assessed.  Three independent experiments were performed.  A significant increase 
(*p<0.0001) in the percentage of interstrand crosslinks (% ICLs) was seen in cells treated 
with combination bortezomib plus melphalan when compared to melphalan treatment 
alone, and when comparing siControl+M to siFANCD2+M.  
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Figure 14.  Low-dose bortezomib does not induce DNA damage.  Comet moment 
analysis of 8226/LR5 cells treated with bortezomib revealed that low-dose (3 nM) 
bortezomib does not induce DNA damage when compared to control-treated samples.  
Three independent experiments were performed.  
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indicate that bortezomib enhances melphalan-induced DNA damage, leading ultimately 
to enhanced melphalan cytotoxicity, likely by targeting FANCD2 and the FA/BRCA 
pathway.     
 
Bortezomib Reduces FA/BRCA Pathway Gene Expression in Patient Specimens   
  To extend the results obtained in vitro to a more clinically relevant model, we 
analyzed FA/BRCA pathway mRNA expression in purified plasma cells from myeloma 
patients prior to and after treatment with bortezomib.  As seen in Figure 15A, a single 
dose of bortezomib reduced FA/BRCA mRNA expression when compared to baseline 
(screening) levels in three patients.  Plasma cells were analyzed from a fourth patient 
prior to therapy, following one dose of bortezomib, two cycles of bortezomib, three 
months after high dose melphalan and stem cell transplant, and at time of relapse (Figure 
15B).  A moderate reduction in FA/BRCA pathway mRNA expression was seen in this 
patient‟s plasma cells following one dose and two cycles of bortezomib.  Certain 
FA/BRCA genes were highly overexpressed, however, at three months post-high dose 
melphalan (as compared to screening levels; Figure 15B).  This patient clinically relapsed 
only five months after completion of therapy, and FA/BRCA pathway mRNA expression 
levels at this time were similar to levels at the time of screening.  Importantly, these 
preliminary results fully support our hypothesis that bortezomib treatment leads to the 
inhibition of FA/BRCA gene expression in MM patients. 
  Clinical response in five patients involved in the bortezomib study was compared 
to modulation of FA/BRCA pathway mRNA expression in these patients following 
treatment with bortezomib.  One patient who showed no response, based on the Bladé 
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multiple myeloma response criteria and as indicated by the levels of IgG in the blood, 
also showed an increase in FA/BRCA pathway mRNA expression levels following one 
dose as well as after two cycles of bortezomib (Figure 16A).  Comparatively, one patient 
displayed a partial response and another showed complete response, and FA/BRCA gene 
expression was reduced in both of these patients following one dose of bortezomib 
treatment (Figure 16 B and C).  Finally, mRNA expression levels of two patients were 
analyzed at the time of relapse and compared to levels post-transplant.  As seen in Figure 
16D, FA/BRCA pathway expression levels showed a general trend of overexpression at 
the time of relapse.  Importantly, these results support our hypothesis that effective 
bortezomib treatment leads to the inhibition of FA/BRCA mRNA expression in MM 
patients.   
  Collectively, the results presented in this section of the dissertation show that 
bortezomib potentiates melphalan activity by inhibiting FA/BRCA pathway gene 
expression, reducing FANCD2 protein expression and foci formation, and enhancing 
DNA damage likely via inhibition of DNA damage repair.  Importantly, these results 
appear to translate to the clinic, as bortezomib was also shown to modulate FA/BRCA 
pathway mRNA expression in multiple myeloma patient specimens. 
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Figure 15.  Bortezomib modulates FA/BRCA pathway mRNA expression in 
myeloma patient specimens.  (A) Bone marrow aspirates were collected in three 
patients prior to treatment with bortezomib (screening) and 24 hours post-bortezomib.  
Plasma cells were isolated via negative selection, with >95% purity, and FA/BRCA 
pathway gene expression was determined using a customized microfluidic card and 
qPCR analysis.  Fold changes were obtained by internally standardizing against GAPDH 
and externally standardizing against the screening sample, equal to 1 (noted by the solid 
red line).  (B) Aspirates from one patient were collected at screening, after one dose of 
bortezomib, following two cycles of bortezomib, 3 months post-transplant, and at time of 
relapse.  FA/BRCA pathway gene expression was analyzed as described in panel A.   
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Figure 16.  Analysis of FA/BRCA pathway mRNA expression in samples taken from 
bortezomib-treated myeloma patients.  Following treatment with bortezomib, 
FA/BRCA pathway mRNA expression was analyzed in a patient who showed (A) no 
response, (B) partial response, and (C) complete response to treatment.  Response was 
assessed based on the Bladé Criteria of response.  Fold changes were obtained by 
internally standardizing against GAPDH and externally standardizing against the 
screening sample, equal to 1 (noted by the solid red line).  (D) Aspirates from two 
patients were collected at time of relapse and externally standardized against 
corresponding samples taken three months post-transplant.   
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Part III: 
NF-B Transcriptionally Regulates the FA/BRCA Pathway 
 Our lab previously reported that many FA/BRCA pathway-related genes are 
overexpressed in cells selected for resistance to melphalan (3-4), and others have also 
implicated this pathway in the acquisition of drug resistance (170, 173).  Furthermore, 
treatment with bortezomib was shown to inhibit expression of many of these genes in 
multiple myeloma cell lines as well as in patient specimens (190), suggesting that these 
genes may be co-regulated.  This portion of the dissertation analyzes the transcriptional 
regulation of members of the FA/BRCA DNA damage repair pathway.  Since NF-B is 
constitutively activated in MM (47, 191), and since bortezomib is a known inhibitor of 
NF-B (59, 78), we hypothesized that NF-B transcriptionally regulates FA/BRCA 
pathway family members.  Analysis of the promoter regions of the FA/BRCA family 
members revealed a number of putative NF-B binding sites, and BMS-345541, a 
specific inhibitor of NF-B, was able to significantly reduce expression of the FA/BRCA 
pathway-related genes analyzed.  Using EMSAs, siRNA experiments, and ChIP analysis, 
we determined that two NF-B subunits, RelB and p50, can bind to the promotor region 
of FANCD2.  We also found that inhibiting RelB/p50 caused a reduction in FANCD2 
protein levels and sensitized cells to melphalan.  Importantly, re-introducing FANCD2 in 
these cells once again conferred resistance.  Taken together, these results indicate that 
NF-B, specifically the RelB and p50 subunits, trancriptionally regulate members of the 
FA/BRCA pathway.      
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Analysis of Promoter Regions of FA/BRCA Pathway Members Reveals Putative NF-
B Binding Sites 
 As a means to determine possible transcriptional regulators of members of the 
FA/BRCA pathway, the promoter regions of the 13 FA family members (fanca, fancb, 
fancc, fancd1/brca2, fancd2, fance, fancf, fancg, fanci, fancj, fancl, fancm, and fancn) and 
brca2 were analyzed.  Putative transcription factor binding sites within the -3000/+1 
segments of the genomic sequences were identified using a public version of P-Match 
and the database provided by TRANSFAC.  As seen in Figure 17, the promoter regions 
of 11 of the 14 genes analyzed contained putative NF-B binding sites.  Interestingly, this 
analysis revealed four putative NF-B binding sites on the promoter region of fancd2.    
 
Low-Dose Bortezomib Inhibits NF-B DNA Binding Activity 
 Using higher doses of bortezomib, others have reported that bortezomib inhibits 
NF-B activity (59, 78).  We hypothesized that NF-B transcriptionally regulates 
members of the FA/BRCA pathway, and so treatment with bortezomib reduces 
FA/BRCA pathway mRNA and protein expression via inhibition of NF-B DNA binding 
activity.  In our system, we wanted to analyze NF-B DNA binding activity in the 
8226/LR5 cell line following treatment with low-dose bortezomib or the combination of 
bortezomib plus melphalan.  Using electrophoretic mobility shift assays (EMSAs), it was 
revealed that exposure to 3 nM bortezomib for 24 hours reduced NF-B DNA binding 
activity, whereas treatment with melphalan enhanced this activity (Figure 18).  
Interestingly, and correlating with our FANCD2 Western blot data, NF-B activity  
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Figure 17. Schematic view of  putative transcription factor (TF)-binding sites in 
FA/BRCA promoter regions.  A public version of „P-Match‟ (http://www.gene-
regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi) and the database provided 
by TRANSFAC (http://www.gene-regulation.com/pub/databases.html) were used to 
identify putative TF-binding sites within -3000/+1 segments of FA/BRCA genomic 
sequences. Using 3 sets of optimized cut-off values, matrix-scores (>0.990) were 
determined.  
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Figure 18.  Bortezomib inhibits NF-B DNA binding activity.  8226/LR5 cells were 
pre-treated with 3 nM bortezomib or vehicle control for eight hours followed by 16 hours 
treatment with melphalan or control.  Samples were collected following eight and 24 
hours treatment with bortezomib and subjected to an electrophoretic mobility shift assay 
(EMSA) to analyze NF-B DNA binding activity.  NF-1 was used as a loading control.   
A film representative of three independent experiments is shown.  
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was attenuated in cells pre-treated with bortezomib and subsequently exposed to 
melphalan, when compared to cells exposed only to melphalan as well as to control cells.     
 
Bortezomib and BMS-345541, a Specific Inhibitor of NF-B, are Antagonistic 
 We next wanted to determine if bortezomib was exacting its cytotoxic effects via 
inhibition of NF-B.  To this end, combination index analysis was performed using 
bortezomib and BMS-345541.  BMS-345541 is a selective inhibitor of the IKK complex 
and a putative anti-tumor agent (192).  If bortezomib is functioning through the NF-B 
pathway, then combining it with a specific inhibitor of this same pathway should result in 
antagonism.  8226/LR5 and U266/LR6 cells were treated simultaneously with varying 
doses of bortezomib and BMS-345541 at a constant molar ratio for a total of 72 hours.  
Analysis of the dose-effect relationship between these two compounds, using the Chou-
Talalay multiple drug effect equation (181), revealed that these compounds are 
antagonistic in their cytotoxic effects (Figure 19), suggesting that the effects of both 
agents are driven by inhibition of the NF-B pathway. 
 
Basal NF-B DNA Binding Activity is Enhanced in Melphalan Resistant Cells 
 Our lab previously reported that melphalan resistant myeloma cells overexpress 
FA/BRCA pathway genes (3-4).  Therefore, we hypothesized that, if NF-B 
transcriptionally regulates members of this pathway, drug resistant multiple myeloma 
cells will display enhanced basal levels of NF-B activity when compared to the drug 
sensitive parental cell lines.  Using EMSAs to measure DNA- 
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Figure 19.  Bortezomib and BMS-345541 are antagonistic.  (A) 8226/LR5 and (B) 
U266/LR6 melphalan resistant myeloma cells were treated with bortezomib and BMS-
345541 for 72 hours and combination index analysis was performed.  Three independent 
experiments were performed, and a representative is shown.  The results show that the 
two drugs act antagonistically in these cell lines, suggesting that both exact their 
cytotoxic effects through the same (NF-B) pathway.  
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bound NF-B complexes, we found that the melphalan resistant 8226/LR5 cells exhibit a 
higher degree of basal NF-B DNA-binding activity relative to the drug sensitive 8226/S 
parental cells (Figure 20A).   
 We next analyzed NF-B DNA binding activity in the 8226/S and 8226/LR5 cell 
lines following melphalan exposure.  We previously reported that interstrand cross-link 
(ICL) accumulation in drug sensitive 8226/S cells is approximately 2-fold higher than 
that of melphalan-resistant 8226/LR5 cells (3, 38).  Therefore, to assess directly the effect 
of acute melphalan exposure on NF-B activation, we treated 8226/S and 8226/LR5 cells 
with 25 M and 50 M melphalan, respectively, as a means to induce a similar amount of 
ICLs.  As shown in Figure 20A, 8226/LR5 cells also exhibit enhanced NF-B DNA 
binding activity following melphalan exposure when compared to melphalan-treated 
8226/S cells.  In both cell lines, melphalan stimulation elicited a peak of NF-B activity 
after 30 minutes, followed by a noticeable decrease in activity at 2 hours post-treatment.  
These findings indicate that acute exposure to melphalan further increases the magnitude, 
but fails to accelerate the rate, of NF-B activation in drug resistant 8226/LR5 cells 
relative to drug sensitive cells.  
 Next, cellular extracts were immunoblotted with a phospho-specific IKK/ 
antibody.  The results showed that IKK was constitutively phosphorylated in 8226/LR5 
cells, but not in 8226/S cells (Figure 20B).  Interestingly, after one hour treatment with 
melphalan, IKK phosphorylation was markedly reduced in 8226/LR5 cells, and no 
IKK activation was ever evident in 8226/S cells.  Furthermore, we were unable to detect 
any basal or melphalan-induced IKK phosphorylation in either cell line. These results 
indicate that chronic exposure of myeloma cells to melphalan engages the specific  
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Figure 20. Basal NF-B DNA binding activity is enhanced in melphalan-resistant 
8226 cells. (A) Nuclear extracts were isolated from melphalan-treated 8226 cells at the 
indicated times and analyzed for NF-B DNA binding activity by EMSA using a 
canonical B site as a probe. Binding to a NF-1 probe was used as a loading control. (B) 
8226/S and 8226/LR5 cells were treated with 25 M and 50 M melphalan, respectively, 
to induce comparable amounts of ICLs between sensitive and resistant cell lines. Cells 
were harvested at the indicated times post-treatment and IKK phosphorylation was 
determined with a -phospho-IKK/IKK specific antibody. Cellular extracts were then 
immunoblotted sequentially with -IKK, -IB, -IB, and --Actin antibodies.  
Representative blots from three independent experiments are shown. 
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phosphorylation of IKK leading to a concomitant increase in basal NF-B DNA-
binding activity. 
 
RelB and p50 Subunits are Responsible for Enhanced FANCD2-Specific NF-B 
DNA Binding Activity in 8226/LR5 Cells 
 To further explore the possibility that NF-B is a transcriptional regulator of the 
FA/BRCA pathway, we analyzed interactions between NF-B and the promoter region of 
FANCD2.  Using FANCD2-specific NF-B binding sites as probes (denoted as I, II, III, 
and IV in Figure 21), nuclear extracts from 8226 cells were analyzed for NF-B DNA-
binding activity.  The results revealed that NF-B DNA-binding activity could only be 
detected with probe IV (Figure 21).  Also, in support of our previous experiments that 
NF-B activity is enhanced in drug resistant cells, extracts from 8226/LR5 cells exhibited 
a substantial increase in FANCD2-bound NF-B complexes relative to the 8226/S cells 
(Figure 21). 
 We next performed gel shift analyses to determine which specific NF-B subunits 
are required for this enhanced DNA binding activity.  Incubation of cell extracts with -
p50 or -RelB antibodies resulted in a complete loss of probe IV-specific electrophoretic 
signals in both the 8226/S and the 8226/LR5 cells (Figure 22A).  Next, we examined the 
effects of siRNA inhibition of the diffrent NF-B subunits on the binding activity of NF-
B toward FANCD2-probe IV.  In correlation with the gel shift assays, knockdown of 
RelB or p50 reduced FANCD2-specific NF-B activity in the 8226/LR5 cells (Figure  
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Figure 21. NF-B DNA binding activity is enhanced in the 8226/LR5 cell line using a 
FANCD2-specific probe.  Nuclear extracts from 8226/S and 8226/LR5 cells were 
analyzed for NF-B DNA binding activity by EMSA using four FANCD2-specific NF-
B probes (I, II, III, and IV). The specificity of each binding reaction was demonstrated 
by competition with a 100-fold excess of unlabeled (cold) NF-B canonical probe.  
22B).  Furthermore, direct immunoblotting of the cellular extracts used for the EMSA 
revealed a decrease in FANCD2 protein levels in RelB- and p50-depleted cells.  A 
representative of three independent experiments is shown. 
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Figure 22. RelB and p50 subunits are responsible for enhanced FANCD2-specific 
NF-B DNA binding activity in the 8226/LR5 cell line.  (A) Nuclear extracts from 
8226/S and 8226/LR5 cells were incubated with the indicated antibodies for 30 min prior 
to EMSA analysis. Binding to FANCD2-Probe IV was used as a measure of NF-B 
activity on FANCD2 promoter region.  (B) 8226/LR5 cells were transfected with the 
indicated siRNAs and examined by EMSA using FANCD2-Probe IV. Binding to the NF-
1 probe was used as a loading control. The bottom panel shows expression levels of 
FANCD2, p65, RelB, c-Rel, p50, p52, and -Actin at 48 h post-transfection.  
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 Using the 8226/S and 8226/LR5 cells, we next performed chromatin 
immunoprecipitation assays to probe for binding between NF-B subunits and the newly 
described NF-B-binding site on the FANCD2 promoter (region IV, Figure 23). 
Quantitative RT-PCR analysis of -NF-B immunoprecipitates with FANCD2-specific 
primers revealed that 8226/LR5 cells exhibited a higher degree of coimmunoprecipitation 
of region IV with RelB, p52, and p50, when compared to 8226/S cells (Figure 23).  In 
contrast, the association of region IV of the FANCD2 promoter with p65 and c-Rel was 
found to be comparable in both cell lines.   
 Based on the results presented above, we conclude that the increase in FANCD2-
specific NF-B activity observed in melphalan-resistant cells is due to the enhanced 
binding of RelB and p50 to the FANCD2 promoter in these cells.  
 
BMS-345541 Downregulates FA/BRCA Pathway mRNA Expression in Melphalan 
Sensitive and Resistant Myeloma Cells 
 To examine the effect of loss of NF-B function on FA/BRCA gene expression, 
we treated 8226 and U266 cells with 4 M BMS-345541 and monitored the levels of 
mRNA transcripts over time, using a customized microfluidic card similar to the one used 
in the bortezomib studies.  Following BMS-345541 treatment, expression of 9 of 11 
genes analyzed in the 8226/S and all 11 genes in the 8226/LR5 cell lines significantly 
decreased in a time-dependent fashion during the first 4-8 hours post-treatment (Figure 
24; Table 3).  However, after 8 hours, exposure to BMS-345541 resulted in a gradual 
recovery in the expression of brca1, fancc, fancl, and rad51 to baseline levels in both cell 
lines.  Finally, FANCD2 protein expression in the 8226/S and 8226/LR5 cell lines was  
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Figure 23.  NF-B subunit binding to the promotor region of FANCD2.  Binding of 
NF-B to the FANCD2 promoter is enhanced in 8226 melphalan-resistant cells as 
determined by chromatin immunoprecipitation analysis.  DNA samples were subjected to 
qPCR using GAPDH and FANCD2-specific primer pairs, schematically represented as 
Control and IV. Results were obtained from three independent trials, and fold changes in 
gene expression were normalized to input samples.  
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Figure 24.  BMS-345541 downregulates FA/BRCA pathway mRNA expression in 
melphalan sensitive and resistant myeloma cell lines.  8226/S and 8226/LR5 cells 
were treated with 4 M BMS-345541 and harvested at the indicated times. FA/BRCA 
gene expression was determined in quadruplicate samples by qPCR using a customized 
microfluidic card. Results depict fold change normalized to vehicle control (VC; i.e., 
DMSO) samples. Three independent experiments were performed.  Statistical analysis 
results can be seen in Table 3.  
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0.00210.00090.00010.00170.06550.5646RAD51C
0.37940.75510.61700.49590.07050.4089RAD51
0.51910.82360.60500.36340.38100.5048FANCL
0.00010.00020.00010.00010.00690.7314FANCG
0.00030.00010.00010.00020.00040.0365FANCF
0.00050.00040.00040.00090.00150.1443FANCE
0.00640.00690.00430.01470.31200.5646FANCD2
0.51910.82360.94410.71250.03480.8832FANCC
0.00040.00100.00020.00150.05730.5649FANCA
0.00040.00040.00020.00140.00380.3958BRCA2
0.37940.70310.60500.02320.09080.9019BRCA1
201612842Time (h)
A
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B
0.0001<0.0001<0.0001<0.00010.00020.0164RAD51C
0.29650.28100.61320.00550.12070.2056RAD51
0.02710.37150.10240.00290.04960.4414FANCL
<0.0001<0.0001<0.0001<0.0001<0.00010.8243FANCG
0.0001<0.0001<0.0001<0.00010.00080.0313FANCF
0.00080.00070.00030.00070.00550.2557FANCE
0.00840.00520.00370.00120.00640.1999FANCD2
0.06170.25570.1172<0.00010.00290.6332FANCC
0.00060.00040.00010.00010.05090.3849FANCA
<0.0001<0.0001<0.0001<0.0001<0.0001<0.0001BRCA2
0.07830.30170.05090.00280.03130.2557BRCA1
201612842Time (h)
 
 
 
Table 3. Statistical analysis of FA/BRCA gene expression after BMS-345541 
treatment  in 8226 cells.  To test the effect of BMS-345541 on FA/BRCA gene 
expression in 8226/S (A) and 8226/LR5 (B) cells, we examined whether fold change of 
gene expression was deviated away from 1. Since each gene showed a non-linear pattern 
of fold change over time (see Figure 19), a linear model with time as a categorical 
explanatory variable was used to test the null hypothesis of fold change=1 at each time 
point for each gene in each cell line. Since we tested 11 FA/BRCA related genes, we 
adjusted for p-value based on the false discovery rate to control for simultaneously 
testing (Benjamini, 1995).  
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also analyzed following exposure to 4 M BMS-345541.  As seen in Figure 25A, 
FANCD2 protein expression is reduced in both cell lines following exposure to BMS-
345541.     
 We next analyzed FA/BRCA pathway mRNA expression in U266 cells using a 
newly designed microfluidic card to incorporate recently added FA members (this card 
allowed for the analysis of all 13 FA genes as well as brca1 and usp1).  Similar to results 
seen in the 8226 cells, exposing U266 cells to BMS-345541 resulted in a dramatic 
decrease in the expression of all 13 FA/BRCA pathway genes after 8 hours, followed by 
a significant recovery in the expression of brca2, fancb, fancc, fancd2, fance, fancf, fancl, 
fancm, and fancn in U266 and/or U266/LR6 cells at 12 hours post-BMS-345541 
treatment (Figure 26; Table 4). The biological significance of the latter event remains 
unclear, and results suggest that compensatory mechanisms in response to a protracted 
loss of NF-B activity are involved in the regulation of the expression of these genes.  
 To further examine the role of NF-B in melphalan resistance, we treated 8226 
cells with increasing amounts of BMS-345541 for 96 hours.  Relative to sensitive cells, 
melphalan-resistant cells displayed a marked decrease in cell growth after BMS-345541 
exposure (Figure 25B).  Taken together, these results suggest that NF-B regulates 
FA/BRCA expression, and that a sustained reduction in FA/BRCA gene expression is 
especially cytotoxic to melphalan-resistant myeloma cells. 
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Figure 25. BMS-345541 reduces FANCD2 protein expression and inhibits growth of 
8226 cells. (A) 8226/S and 8226/LR5 cells were treated with 4 M BMS-345541 for 12, 
24, 36, 48, and 72 h. Cellular extracts were harvested, resolved by SDS-PAGE, and 
immunoblotted with the indicated antibodies. -Actin served as control for sample 
loading. (B) 8226/S and 8226/LR5 cells were treated with increasing amounts of BMS-
345541 for 96 h and the percentage of cell growth was determined using a standard 
methyl-thiazol tetrazolium (MTT) colorimetric assay. Results (mean +/- SEM) were 
obtained from four independent trials.  
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Figure 26. BMS-345541 reduces FA/BRCA pathway mRNA expression in U266 and 
U266/LR6 cell lines.  U266 and U266/LR6 cells were treated with BMS-345541 as 
described in Figure 24.  A newly designed microfluidic card was used to measure the 
expression of all 13 FA/BRCA genes, as well as brca1 and usp1. Results depict fold 
change normalized to vehicle control (VC; i.e., DMSO) in triplicate samples. Statistical 
analysis results can be seen in Table 4.  
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<0.0001<0.00010.0002<0.00010.00570.0043FANCJ
<0.0001<0.0001<0.0001<0.0001<0.00010.0001FANCI
<0.0001<0.0001<0.0001<0.0001<0.00010.8028FANCG
<0.0001<0.0001<0.0001<0.0001<0.00010.0022FANCF
<0.0001<0.00010.0004<0.0001<0.00010.0002FANCE
<0.0001<0.00010.2105<0.00010.00050.1610FANCD2
0.00090.0028<0.00010.00080.01180.8028FANCC
0.00390.00080.0398<0.00010.00230.6186FANCB
<0.0001<0.00010.0026<0.00010.00010.3032FANCA
<0.0001<0.00010.0001<0.00010.00350.2013BRCA2
<0.0001<0.0001<0.0001<0.00010.00010.8900BRCA1
201612842Time (h)
0.00350.00010.1442<0.00010.00010.8233FANCL
<0.0001<0.0001<0.0001<0.0001<0.0001<0.0001FANCM
<0.0001<0.0001<0.0001<0.0001<0.0001<0.0001FANCN
<0.0001<0.00010.0013<0.0001<0.0001<0.0001USP1
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B
<0.0001<0.0001<0.0001<0.0001<0.00010.0012FANCJ
<0.0001<0.0001<0.0001<0.0001<0.00010.0010FANCI
<0.0001<0.0001<0.0001<0.0001<0.00010.0008FANCG
<0.0001<0.0001<0.0001<0.0001<0.0001<0.0001FANCF
0.0222<0.00010.0070<0.0001<0.00010.0001FANCE
<0.0001<0.0001<0.0001<0.0001<0.00010.0022FANCD2
0.00020.0007<0.0001<0.0001<0.00010.0019FANCC
0.0001<0.00010.0017<0.0001<0.00010.0003FANCB
<0.0001<0.00010.0003<0.00010.00010.0493FANCA
<0.0001<0.0001<0.0001<0.0001<0.00010.0009BRCA2
<0.0001<0.0001<0.0001<0.0001<0.0001<0.0001BRCA1
201612842Time (h)
0.08980.00020.02020.00030.00050.3242FANCL
0.0003<0.00010.0358<0.0001<0.0001<0.0001FANCM
<0.0001<0.0001<0.0001<0.0001<0.0001<0.0001FANCN
0.00020.00030.00690.0001<0.0001<0.0001USP1
 
 
 
Table 4. Statistical analysis of FA/BRCA gene expression after BMS-345541 
treatment in U266 cells.  To test the effect of BMS-345541 on FA/BRCA gene 
expression in U266 (A) and U266/LR6 (B) cells, we examined whether fold change of 
gene expression was deviated away from 1. Since each gene showed a non-linear pattern 
of fold change over time (see Figure 21), a linear model with time as a categorical 
explanatory variable was used to test the null hypothesis of fold change=1 at each time 
point for each gene in each cell line. Since we tested 15 FA/BRCA related genes, we 
adjusted for p value based on the false discovery rate to control for simultaneous testing 
(Benjamini, 1995).  
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Loss of RelB/p50 Reduces FANCD2 Expression and Re-Sensitizes 8226/LR5 Cells to 
Melphalan 
 To further examine the role of NF-B in the regulation of FANCD2 expression 
and function following treatment with melphalan, we determined whether RelB/p50 
double-knockdown was sufficient to sensitize 8226/LR5 cells to melphalan. Cells were 
transfected with control or RelB and p50 siRNAs, then exposed to varying doses of 
melphalan for 24 hours.  Apoptosis, as indicated by the amount of DNA fragmentation, 
was determined using the Diffusion Apoptosis Slide Halo (DASH) assay.  Treatment of 
8226/LR5 cells with RelB and p50 siRNAs significantly sensitized these cells to 
melphalan-induced cell death (Figure 27A; Table 5).  Furthermore, relative to wild type 
8226/LR5 cells, RelB/p50-depleted 8226/LR5 cells displayed a dramatic increase in ICLs 
after exposure to melphalan, with levels of DNA damage significantly surpassing those 
observed in melphalan-sensitive cells (Figure 27B; Table 6).  Statistical analysis also 
showed that the results presented in Figures 27A and 27B were positively correlated at 
each dose of melphalan tested, suggesting that loss of cell viability is causally linked to 
melphalan-induced ICL formation (Table 7).  Importantly, consistent with the results 
obtained with RelB- and p50-depleted cells (Figure 22), RelB/p50 double-knockdown 
caused a striking decrease in FANCD2 protein expression (Figure 27C).  Finally, re-
expression of FANCD2 in the RelB/p50-depleted cells restored melphalan resistance 
(Figure 27D).  These results indicate that RelB and p50 protect 8226/LR5 cells from 
melphalan-induced apoptosis, at least in part, by regulating expression of the DNA 
damage response protein FANCD2.  Collectively, the results presented in this section 
demonstrate that NF-B, specifically the RelB and p50 subunits, positively regulates 
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FA/BRCA pathway expression, and provide evidence for targeting this pathway as a 
means to overcome or even circumvent drug resistance.   
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Figure 27. Loss of RelB and p50 re-sensitizes 8226/LR5 cells to melphalan treatment 
and reduces FANCD2 expression.  (A) 8226/LR5 cells were treated with the indicated 
siRNAs for 48 h, stimulated with 25-100 M melphalan or vehicle control for 24 h, and 
the relative amount of DNA fragmentation was determined by DASH Assay. Wild-type 
8226/S and 8226/LR5 cells were used as reference samples. (B) At 48 h post-
transfection, the cells were exposed to 25-100 M melphalan for 2 h, damaged with 9 Gy 
ionizing radiation, and interstrand cross-links were evaluated using the Alkaline Comet 
Assay. Wild-type 8226/S and 8226/LR5 cells were used as reference samples.  (C) 
Representative immunoblots from 8226/LR5 cells transfected with siControl (control) or 
RelB and p50 siRNAs, as well as from cells transfected with RelB/p50 siRNAs plus 
pIRES-FANCD2.  (D) 8226/LR5 cells were treated with the indicated siRNAs, and after 
24 h, the cells were transfected with empty vector or untagged, full-length FANCD2 
(pIRES-FANCD2). At 48 h post-siRNA  transfection, the cells were stimulated for 24 h 
with either vehicle control (VC) or 50 μM melphalan, and the relative amount of DNA 
fragmentation was determined as described in panel A. Results (mean ± S.E) were 
obtained from three independent trials. 
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Melphalan (M)
Adjusted P-value 
(Tukey's Method)
0.00050.00110.00420.9956LR5 RelB/p50 - LR5 siControl
0.00020.00040.00780.48978226/S - LR5
0.00380.00980.00640.6548LR5 RelB/p50 - LR5
0.30530.33020.98560.5300LR5 siControl - LR5
10050250
<0.00010.00010.00510.99988226/S - LR5 siControl
0.07150.09660.99830.98988226/S - LR5 RelB/p50
 
 
 
Table 5. Statistical analysis of melphalan-induced DNA fragmentation in RelB/p50 
siRNA-treated cells. Analysis of variance (ANOVA) was used to compare the radius 
difference (log scale) of cell death between four groups: (8226/S, LR5 RelB/p50, LR5 
siControl, and LR5), at each dose level (0, 25, 50, and 100 M) in Figure 22A. Multiple 
comparisons of nuclear DNA diffusion were adjusted with the Tukey‟s Honest 
Significance Difference method (Miller, 1981). A P-value <0.05 was considered 
significant. These results show that siRNA-mediated depletion of RelB and p50 in 
8226/LR5 cells significantly increases the magnitude of cell death induced by melphalan 
stimulation.  
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0.0082-0.0028226/S – LR5
0.0202-0.002LR5 RelB/p50 – LR5
0.50150.001LR5 siControl – LR5
Linear Slope Difference
<0.00010.2548226/S – LR5
<0.00010.377LR5 RelB/p50 – LR5
0.0747-0.060LR5 siControl – LR5
Intercept Difference 
(Melphalan = 25 M)
P-valueEstimate
 
 
 
Table 6 Statistical analysis of melphalan-induced ICL in RelB/p50 depleted cells. A 
linear regression model was used to analyze the percentage of ICLs obtained from Figure 
22B cell populations. Intercept and slope differences were determined using 8226/LR5 
cells as a reference cell line. A P-value <0.05 was considered significant. These results 
show that RelB/p50-depleted cells display a significant increase in ICL formation after 
exposure to melphalan relative to wild-type or siControl-transfected 8226/LR5 cells. 
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Table 7. Correlation between melphalan-induced ICL and DNA fragmentation.  
Relationship of DNA fragmentation and ICL was assessed by Pearson correlation. Note 
that a zero correlation indicates no association between the two variables while a 
correlation close to 1 suggests a strong positive correlation. These results show that ICL 
formation and DNA fragmentation can be positively correlated in 8226 cells after 
melphalan-induced stress.  
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Part IV: 
Post-Transcriptional Regulation of FANCD2 by Bortezomib 
 The results presented in Parts II and III of this dissertation show that NF-B 
transcriptionally regulates members of the FA/BRCA DNA damage repair pathway, and 
that bortezomib can inhibit FA/BRCA pathway mRNA expression, as well as FANCD2 
protein expression and foci formation.  We also show that bortezomib enhances 
melphalan-induced DNA damage, likely via inhibition of FA/BRCA pathway-mediated 
DNA damage repair.  Since we found that FA/BRCA pathway mRNA expression was 
attenuated by bortezomib, but not to the same extent as the inhibition of FANCD2 protein 
expression, we analyzed regulation of the FA/BRCA pathway downstream of 
transcriptional regulation.  We hypothesized that bortezomib not only reduces FANCD2 
protein expression via reduction of FANCD2 mRNA levels, but also by directly targeting 
FANCD2 protein.  Therefore, we analyzed FANCD2 protein stability via stable isotopic 
labeling of amino acids in cell culture (SILAC) and mass spectrometry.  We also 
analyzed the effects of various miRNAs on the expression of FANCD2, since miRNAs 
have been shown to repress translation without cleavage of the mRNA (193-194).  
Finally, we studied ATR activation and cell cycle progression in cells treated with 
bortezomib.  In this section, we show that bortezomib inhibits FANCD2 synthesis and 
ATR activation, and also overcomes melphalan-induced S-phase arrest. 
 
Bortezomib Inhibits FANCD2 Synthesis 
 FANCD2 protein stability was analyzed in bortezomib-treated 8226/LR5 cells via 
stable isotopic labeling of amino acids in cell culture (SILAC) and mass spectrometry.  
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Cells were labeled with “heavy” media containing stable isotopes of lysine and arginine 
for six doubling times (approximately seven days).  The media was then replaced with 
“light” (regular) media, containing the naturally-occurring forms of lysine and arginine.  
At the time of addition of the light media, cells were also treated with vehicle control or 3 
nM bortezomib, and samples were collected at 0, 4, 8, 12, 24 and 36 hours post-
bortezomib treatment.  Incorporation of “heavy” lysine and arginine during protein 
synthesis causes a shift in the molecular weight of the protein that can be detected by 
mass spectrometry.  Therefore, we were able to analyze FANCD2 degradation (as 
indicated by reduction in “heavy” label over time) and synthesis (as indicated by 
increased “light” expression over time) following bortezomib treatment, based on seven 
FANCD2-specific peptides.  Control- and bortezomib- treated lysates were separated on a 
gel (Figure 28A; shows equal loading of lysates), and the FANCD2 bands were excised 
and analyzed via mass spectrometry.  
 Total FANCD2 protein expression, as indicated by the sum of the heavy and light 
labeled FANCD2, is reduced at 24 hours in bortezomib-treated cells when compared to 
control-treated cells (Figure 28B).  These findings are similar to the results seen via 
Western blot analysis of FANCD2 protein expression following bortezomib treatment 
(Figure 10).  Degradation of FANCD2 protein, as indicated by reduction in the “heavy” 
protein, is similar in control- and bortezomib-treated cells up to 12 hours (Figure 28C). 
At 24 and 36 hours, however, a slight increase in FANCD2 degradation is seen in the 
bortezomib-treated cells.  FANCD2 protein synthesis, on the other hand, is drastically 
inhibited by bortezomib at 24 and 36 hours post-treatment (Figure 28D).  In total, these  
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Figure 28.  Bortezomib inhibits FANCD2 protein synthesis.  Stable isotopic labeling of 
amino acids in cell culture (SILAC) was performed on 8226/LR5 cells to analyze 
FANCD2 synthesis and degradation following treatment with bortezomib.  Cells were 
labeled with “heavy” media containing stable isotopes of lysine and arginine for six 
doubling times (approximately seven days).  The media was then replaced with regular 
media and cells were immediately treated with control or 3 nM bortezomib for 4,8, 12, 24 
and 36 hours.  Mass spectrometry was performed using FANCD2-specific peptides.  Two 
independent experiments were performed, both showed the same trend, and a 
representative is shown.  (A) Coomassie Brilliant Blue stained gel to show equal loading.  
Bands from this gel were excised for analysis.  (B)  Total FANCD2 protein expression, as 
detected by mass spectrometry, following bortezomib treatment for indicated times.  (C)  
FANCD2 degradation (as indicated by reduction in “heavy” label over time) and 
synthesis (as indicated by increased “light” expression over time) following bortezomib 
treatment and based on seven FANCD2-specific peptides.    
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results show that bortezomib reduces FANCD2 protein expression by inhibiting 
FANCD2 synthesis.  
 
Bortezomib Overcomes Melphalan-Induced S-Phase Arrest 
 We next wanted to determine if the reduction of FANCD2 protein expression and 
foci formation by bortezomib could be due to induction of a cell cycle arrest.  Previous 
reports have shown that FANCD2 monoubiquitination and foci formation is S-phase 
specific (156), and bortezomib is known to reduce the percentage of cells in S-phase 
(188-189).  As shown in Figure 12, melphalan drastically increases the percentage of 
cells in S-phase at 24 hours, but pre-treatment with bortezomib reduces this number.  We 
next wanted to determine if bortezomib was arresting these cells at a specific phase of the 
cell cycle, and so analyzed cell cycle progression at later time points.  As shown in Figure 
29, melphalan arrests cells in the S-phase of the cell cycle.  Bortezomib, on the other 
hand, induces a G0/G1 arrest.  Importantly, the melphalan-induced S-phase arrest is 
overcome by bortezomib, and cells treated with the combination of these two drugs also 
arrest at G0/G1 (Figure 29). 
 Following DNA damage, the ATR kinase can be activated and induce an S-phase 
cell cycle checkpoint (195).  ATR has also been shown to phosphorylate FANCD2, and 
this event promotes the monoubiquitination/activation of FANCD2 (64).  Based on these 
studies, we hypothesized that bortezomib inhibits ATR activation as a mechanism to 
overcome the S-phase arrest induced by melphalan.  We therefore treated cells with 3 nM 
bortezomib, and analyzed ATR activation (as indicated by phosphorylated ATR).  As 
shown in Figure 30, ATR phosphorylation is reduced in cells treated with bortezomib for  
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Figure 29.  Bortezomib overcomes melphalan-induced S-phase arrest and arrests 
cells in G0/G1.  8226/LR5 cells were treated with control or 3 nM bortezomib for 8 
hours, followed by treatment with 25 mM melphalan, and collected from 24-48 hours 
post-treatment.  Cell cycle analysis was performed by labeling with BrdU and PI.  The 
average and SEM of four independent experiments are shown.  
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eight hours.  Futhermore, ATR is known to phosphorylate p53 at serine 15, and this 
phosphorylation event is also slightly inhibited following eight hours treatment with 
bortezomib, when compared to control-treated cells (Figure 30).  Importantly, in the 
combination studies of bortezomib plus melphalan described above, cells are pre-treated 
with bortezomib for eight hours before the addition of melphalan.  The results presented 
in this section show that low-dose bortezomib arrests cells in G0/G1 and also overcomes 
the S-phase arrest induced by melphalan, likely via inhibition of ATR activity. 
   
FANCD2 Expression is Not Regulated by Hsa-miR-23a or Hsa-miR-27 
 MicroRNAs (miRNAs) are short RNAs, approximately 22 nucleotides in length, 
that do not code for protein, but are known to regulate gene expression post-
transcriptionally (196-197).  MiRNAs bind to the untranslated regions of mRNAs and 
inhibit translation (194).  We hypothesized that bortezomib enhances expression of 
miRNAs that inhibit the translation of FANCD2.  To this end, we treated 8226/LR5 cells 
with vehicle control or 3 nM bortezomib for eight hours, and a microarray of miRNA 
expression was analyzed.  The results revealed that 33 miRNAs were differentially 
expressed in bortezomib-treated versus control-treated samples (Figure 31).   
 We next wanted to determine if any of the miRNAs altered by bortezomib 
treatment targeted FANCD2.  We analyzed these 33 miRNAs using TARGETSCAN  
software and determined, based on sequence homology, that hsa-miR-23a could 
potentially target FANCD2.  We next transfected 8226/LR5 cells with pre-miRNAs  
specific for hsa-miR-23a.  Pre-miRNAs are cleaved inside the cell to generate the short, 
functional miRNA.  As indicated by q-PCR analysis of hsa-miR-23a, transfection of  
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Figure 30.  Bortezomib inhibits ATR activation.  8226/LR5 myeloma cells were treated 
with 3 nM bortezomib and samples were collected at 2, 8 and 24 hours post-treatment.  
ATR activation, as indicated by phospho-ATR and phospho-p53, was analyzed.  Three 
independent experiments were performed and a representative blot is shown. 
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8226/LR5 cells with pre-miR-23a increased expression of miR-23a by approximately 
100-fold or greater when compared to control-transfected cells.  This miRNA did not, 
however, affect expression of FANCD2 protein (Figure 32A).  As expected, transfection 
of cells with pre-miR-23a did, however, reduce expression of GLS, a known target of 
miR-23a.   
 We also analyzed the effect of hsa-miR-27 on FANCD2 expression.  This miRNA 
was one of the most highly expressed following bortezomib treatment.  In these 
experiments, 8226/LR5 cells were transfected with an inhibitor of miR-27.  Transfection 
with the anti-miR-27 caused a 2- to 4-fold reduction in hsa-miR-27 expression.  Western 
blot analysis revealed overexpression FADD (the positive control) in anti-miR-27 
transfected cells, but no alteration of FANCD2 expression was observed (Figure 32B).  In 
total, these results show that treatment with bortezomib modulates miRNA expression, 
but FANCD2 is not a target of hsa-miR-23a or hsa-miR-27.          
 Based on the work presented in this section of the dissertation, we conclude that 
reduced FANCD2 protein expression following bortezomib treatment is not due solely to 
inhibition of transcription by NF-B and reduction of FANCD2 mRNA expression.  
Bortezomib also inhibits FANCD2 protein synthesis and inhibits ATR activation, 
overcoming melphalan-induced S-phase arrest. 
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Figure 31.  miRNA analysis of bortezomib-treated 8226/LR5 myeloma cells.  miRNA 
expression was analyzed in 8226/LR5 cells treated with vehicle control or 3 nM 
bortezomib for eight hours.  Microarray analysis of miRNAs revealed 33 differentially 
expressed miRNAs in bortezomib-treated cells when compared to control-treated cells.   
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Figure 32. FANCD2 is not targeted by hsa-miR-23a or hsa-miR-27.  (A) 8226/LR5 cells were 
transfected with 50 nM pre-miR-23a oligonucleotide, as a means to overexpress hsa-miR-23a in 
these cells.  Western blot analysis of FANCD2 following transfection shows no change in 
FANCD2 expression in miR-23a overexpressing 8226/LR5 cells when compared to control-
transfected cells.  Lysates were also probed with -glutaminase (GLS) antibody as a positive 
control, and reductions in GLS expression were seen 24-72 hours post-transfection.  (B)  Western 
blot analysis of FANCD2 following transfection shows no change in FANCD2 expression in 
miR-27 overexpressing 8226/LR5 cells when compared to control-transfected cells. Lysates were 
also probed with -FADD antibody as a positive control, and and increase in FADD expression 
were seen 72 hours post-transfection.
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DISCUSSION 
 
Members of the FA/BRCA Pathway are Overexpressed in Drug Resistant Cancer 
Cells and Can be Inhibited by Bortezomib 
 We recently reported that the FA/BRCA DNA damage repair pathway is 
significantly involved in melphalan resistance in MM cells (3-4).  Specifically, we 
showed overexpression of FA/BRCA pathway genes in the melphalan resistant 8226/LR5 
and U266/LR6 cell lines when compared to their respective drug sensitive parental cell 
lines.  Futhermore, this overexpression was determined to be causative for resistance, as 
inhibition of FANCF in the drug resistant8226/LR5 cells reversed resistance, and 
overexpression of FANCF in the drug sensitive 8226/S cells conferred resistance to 
melphalan (3).  Similarly, Dr. Alan D‟Andrea‟s group reported that the FA/BRCA 
pathway is responsible for resistance of glioma cells to the alkylating agents TMZ and 
BCNU, and activation of FANCF has been implicated in cisplatin resistance as well (170, 
173).  In the first section of this dissertation, we extend the work performed by our lab 
and others by analyzing FA/BRCA pathway mRNA expression in drug sensitive and drug 
resistant tumor cell lines.  Consistent with previous reports, prostate and ovarian cancer 
cell lines selected for resistance to the alkylating agents melphalan and cisplatin were 
found to overexpress many FA/BRCA pathway genes.  These results suggest that the 
FA/BRCA pathway mediates resistance to alkylating agents in a variety of tumor types, 
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and provide impetus for discovering new agents that target this pathway as a means of 
overcoming or circumventing drug resistance. 
 FA/BRCA pathway mRNA expression was also analyzed in 8226 cells selected 
for resistance to doxorubicin and mitoxantrone.  These drugs inhibit the function of 
topoisomerase II, resulting in the accumulation of double strand breaks (DSBs).  
Interestingly, acquired resistance to doxorubicin and mitoxantrone did not result in global 
overexpression of FA/BRCA pathway genes, but rather a specific enhancement of 
FANCF expression.  The consequence of overexpression of a single FA protein is 
unknown.  All FA proteins are required for core complex function and subsequent 
activation of the ID complex, but the stoichiometry of FA core complex subunits is still 
undetermined (198).  FANCF is a flexible adaptor protein, responsible for stabilizing the 
interaction between FANCA and FANCG and between FANCC and FANCE (145).  It is 
possible that enhanced FANCF expression results in more efficient and/or increased 
formation of the core complex by increasing the binding of uncomplexed FANC proteins 
within the nucleus, leading ultimately to enhanced DNA damage repair and drug 
resistance.  Alternatively, FANCF may function outside of the FA/BRCA pathway, 
interacting with other proteins to mediate drug resistance in these cells.  Finally, it is also 
plausible that overexpression of a single FA/BRCA pathway subunit may not be 
causative for resistance to topoisomerase II inhibitors, and FANCF overexpression is not 
responsible for the drug resistant phenotype observed in these cells.  
 The emergence of drug resistance remains the largest hurdle in the effective 
treatment of myeloma.  Thus, preventing or reversing drug resistance via combination 
therapy is likely vital for curing this disease.  To this end, it has been reported that 
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bortezomib enhances sensitivity to chemotherapeutic agents, including melphalan, both 
in vitro and in patient specimens (28, 59, 78).  Based on these observations and our 
knowledge that FA/BRCA pathway overexpression is responsible for melphalan 
resistance, we hypothesized that bortezomib enhances melphalan cytotoxicity by 
inhibiting DNA repair associated with the FA/BRCA pathway.  In support of this 
hypothesis, the experiments presented in Part II of this dissertation show that bortezomib 
inhibits FA/BRCA pathway expression and function.  First, we show that bortezomib 
attenuates mRNA expression of FA/BRCA pathway family members in the drug 
sensitive and drug resistant 8226/S and 8226/LR5 cell lines.  In addition to reducing gene 
expression, bortezomib inhibited FANCD2 protein expression and foci formation, even in 
the presence of melphalan, in two melphalan resistant cell lines.  Bortezomib also 
enhanced melphalan-induced DNA damage, likely through inhibition of FANCD2 and 
thus abrogation of DNA repair.  Similar to these results, Jacquemont et. al. reported that 
proteasome function is required for the monoubiquitination of FANCD2 and FANCD2 
foci formation (176).  These results provide insight into the mechanism by which 
bortezomib potentiates the cytotoxicity of DNA damaging agents.  
  Based on our results, we believe that the dose scheduling of bortezomib plus 
melphalan needs to be considered when attempting to improve therapeutic results.  We 
speculate that pre-treatment with low dose bortezomib followed by melphalan may be 
necessary to capitalize on the ability of bortezomib to inhibit the FA/BRCA DNA 
damage response pathway.  Conceptually, the cytotoxic effects of melphalan due to 
interstrand crosslink formation may be enhanced if DNA damage repair function via the 
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FA/BRCA pathway is first inhibited.  We believe that this dosing schedule will result in 
more durable remissions and thus should be explored further.   
  Exploiting the FA/BRCA pathway-inhibitory effects of bortezomib by combining 
this drug with chemotherapeutic agents other than melphalan may also prove effective in 
treating myeloma.  For example, BRCA1 and BRCA2-deficient tumor cells are sensitive 
to inhibiton of poly(ADP-ribose) polymerase (PARP) (199-200).  PARP is a key enzyme 
involved in base excision repair, and its inhibition leads to the accumulation of double 
strand breaks (DSBs), which cannot be repaired in cells that are deficient in homologous 
recombination (HR) repair (201).  Therefore, combining PARP inhibitors with 
bortezomib, a drug that we show inhibits BRCA1, BRCA2, and other FA proteins 
involved in HR repair, may prove to be an effective strategy to treat patients with 
myeloma.  As another example, combining bortezomib with Imexon may also prove 
effective.  Imexon is a small molecule that induces accumulation of reactive oxygen 
species (ROS) (202).  ROS accumulation has also been observed in bortezomib-treated 
cells (203), and FA patient cells are hypersensitive to ROS (204).  The cytotoxic effects 
of bortezomib plus Imexon are synergistic in myeloma tumor cell lines (202), and we 
postulate that this enhanced cytotoxicity may be due to the detrimental effects of ROS 
accumulation in FA/BRCA pathway-inhibited cells.          
In summary, the findings presented in Parts I and II of this dissertation show that 
the FA/BRCA DNA damage repair pathway is upregulated in a variety of tumor types 
selected for resistance to alkylating agents, and that bortezomib potentiates melphalan 
cytotoxicity, at least in part, via suppression of this pathway.  Based on these studies, we 
propose that the therapeutic index of melphalan, and potentially other agents, in myeloma 
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patients can be greatly enhanced by targeting the FA/BRCA DNA damage repair 
pathway. 
 
Mechanisms by Which Bortezomib Inhibits FA/BRCA Pathway Expression 
 The studies presented in Part II of this dissertation, and as described in the 
discussion above, show that bortezomib treatment decreases expression of many 
FA/BRCA pathway genes in both melphalan sensitive and melphalan resistant cell lines, 
as well as in MM patient specimens, suggesting that these genes may be co-regulated.  
Furthermore, we and others have shown that bortezomib inhibits NF-B activity (59, 78), 
and combination index analysis studies performed by our lab revealed antagonism when 
myeloma cells were treated simultaneously with bortezomib and BMS-345541, a specific 
inhibitor of the NF-B pathway.  The results suggest that both drugs exact their cytotoxic 
effects via inhibition of this pathway, and we therefore hypothesized that NF-B is an 
upstream mediator of the FA/BRCA pathway.  
The transcriptional regulation of FA/BRCA pathway genes is largely unknown.  
Analysis of the promoter regions of FA/BRCA pathway genes revealed putative NF-B 
binding sites on 12 of these genes (brca1, brca2, Fanca, fancc, fancd2, fance, fancf, 
fancg, fanci, fancj, fancl, fancm, and fancn).   In Part III of this dissertation, we report for 
the first time that NF-B functions as a transcriptional regulator of the FA/BRCA 
pathway.   
Our lab previously reported that FA/BRCA pathway mRNA levels are 
overexpressed in melphalan resistant myeloma cells.  Interestingly, the melphalan 
resistant 8226/LR5 cells also exhibit an increase in basal NF-B DNA-binding activity 
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when compared to the 8226/S cells, which we hypothesized could explain the enhanced 
expression of FA/BRCA pathway genes.  Gel shift assays and siRNA inhibition of NF-
B subunits identified RelB and p50 as the subunits responsible for this enhanced 
binding activity.  Additionally, chromatin immunoprecipitation (ChIP) analysis revealed 
that the level of NF-B activity observed in the melphalan resistant 8226/LR5 cells is 
attributable to increased binding of RelB and p50 to the FANCD2 promoter.  As 
expected, FANCD2 protein expression was drastically decreased in RelB/p50-depleted 
8226/LR5.  Importantly, these RelB/p50-depeleted cells were no longer melphalan 
resistant, as indicated by an increase in ICL and DNA fragmentation and the onset of 
apoptosis following acute exposure to melphalan.  Conversely, re-expressing FANCD2 in 
RelB/p50-depleted cells conferred resistance to melphalan.  Collectively, these findings 
indicate that attenuated FANCD2 expression and function in RelB/p50-depleted cells is 
responsible for the enhanced melphalan sensitivity seen in these cells.  
 Interestingly, we demonstrate that chronic exposure of 8226 cells to melphalan 
engages the specific phosphorylation of IKK, which in turn leads to augmented basal 
NF-B DNA-binding activity in these cells.  Based on the finding that IKK is 
constitutively phosphorylated in melphalan resistant cells, our results suggest that the 
alternative pathway of NF-B activation protects these cells against apoptotic stress 
imposed by the alkylating agent melphalan.  
 FANCD2-specific NF-B activity was greatly enhanced in 8226/LR5 cells 
relative to the drug sensitive 8226/S cell line, and our results implicate the RelB and p50 
subunits in this enhanced binding activity.  Depletion of RelB or p50 expression 
abolished the basal DNA-binding activity of NF-B in 8226 cells.  We hypothesize that 
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other NF-B subunits may compensate for loss of RelB or p50 in the regulation of 
FANCD2 expression in myeloma cells.  This model is consistent with our finding that 
p65, c-Rel, and p52 can also bind to the FANCD2 promoter in 8226 cells.  Moreover, 
relative to control cells, 8226/LR5 cells also exhibited a higher degree of 
coimmunoprecipitation of the FANCD2 promoter with p52.  Since RelB stability requires 
multi-domain interactions with p100/p52 (205), it is also plausible that this NF-B 
precursor/product pair promotes the stable formation of a transcriptionally active 
RelB/p50 heterodimer in melphalan resistant cells. The mechanism of p50 activation in 
these cells is unknown, although a recent report indicates that p100 mediates p65/p50 
activation in response to noncanonical NF-B signaling pathways (206).  
 We speculate that prolonged or high-intensity replicative stress in myeloma cells 
triggers the transcriptional activation of FA/BRCA genes as a means to ameliorate fork 
progression and repair.  In Part III of this dissertation, we demonstrate that NF-B can 
transcriptionally regulate FA/BRCA pathway genes.  Stimulation of melphalan sensitive 
and resistant 8226 and U266 cells with BMS-345541, a known inhibitor of NF-B 
activation, elicited a rapid decline in FA/BRCA mRNA levels.  However, at later time 
points and in some of the FA/BRCA genes analyzed, gene expression was seen to either 
transiently or stably recover to close to baseline levels.  It is likely that acquired 
melphalan resistance involves the coordinated effects of a number of DNA damage-
induced transcription factors, resulting in transient oscillations of FA/BRCA gene 
expression.  For example, Hoskins et. al. reported that FA gene expression is regulated by 
members of the Rb/E2F family (207).  It is plausible that this family of transcription 
factors can compensate for the loss of NF-B following BMS-345541 treatment and 
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induce transcription of FA/BRCA pathway genes.  Alternatively, it is possible that 
FA/BRCA gene expression is regulated by epigenetic modifications of promoter regions.  
In this regard, chronic exposure of myeloma cells to melphalan may promote 
demethylation of FA/BRCA promoter regions, granting DNA damage-induced 
transcriptional regulators, such as NF-B, free access to transcriptional start sites, 
eventually resulting in enhanced FA/BRCA pathway expression. 
 NF-B is known to play a pivotal role in MM tumorigenesis and drug resistance.  
NF-B is constitutively activated in multiple myeloma, is overexpressed in drug resistant 
myeloma cell lines, and is elevated in patient specimens following chemotherapeutic 
treatment and at time of relapse (37, 55-57, 59-60, 62).  We postulate that genetic 
activation of the alternative NF-B pathway, specifically the RelB and p50 subunits, 
allows malignant plasma cells to gain independence from the rich milieu of growth 
factors and cytokines produced in the bone marrow microenvironment.  Interestingly, 
Landowski et. al. reported that these same subunits are upregulated following MM cell 
adhesion to fibronectin (FN), a component of the bone marrow microenvironment (58).  
Adhesion to this extracellular matrix protein induces a transient form of drug resistance 
in the adhered tumor cells (208).  Based on the specific enhancement of RelB and p50 in 
adhered cells, it is plausible that the FA/BRCA DNA damage repair pathway is important 
not only for acquired resistance, but also contributes to the de novo drug resistance 
phenotype.  Furthermore, a recent report demonstrated that HES1, the downstream 
effector protein of Notch1, interacts with the FA core complex and is required for 
FANCD2 monoubiquitination (127).  Notch1 signaling is upregulated following cellular 
adhesion to bone marrow stromal cells and confers resistance in these tumor cells (41).  
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These reports provide another potential link between the FA/BRCA pathway and de novo 
drug resistance; upregulation of Notch1 in adhered cells enhances HES1 signaling, and 
may result in enhanced expression of the FA/BRCA pathway leading to drug resistance.       
 In summary, the results presented in Part III of this dissertation show for the first 
time that NF-B plays an important role in the regulation of FA/BRCA gene expression 
in human multiple myeloma cells.  This conclusion is further substantiated by a recent 
report that curcumin analogs inhibit the FA pathway via inhibition of NF-kB activity 
(209).  The importance of this work is best illustrated by the observation that a sustained 
reduction in FA/BRCA gene expression is especially cytotoxic to melphalan-resistant 
cells.  It is likely that these cells have become addicted to FA/BRCA-mediated genome 
surveillance and DNA repair.  We therefore postulate that targeting the FA/BRCA 
pathway directly, or indirectly via inhibition of NF-B, will enhance the cytotoxic effects 
of commonly used chemotherapeutic agents. 
 Based on the studies presented in this dissertation, we propose that targeting the 
proteasome accentuates melphalan response by reducing FA/BRCA gene expression via 
inhibition of NF-B, and blocking activation of FANCD2, thereby inhibiting DNA 
damage repair following drug treatment.  The observation that FA/BRCA pathway 
mRNA expression was attenuated by bortezomib, but not to the same degree as the 
inhibition of FANCD2 protein expression, suggests that bortezomib not only reduces 
FANCD2 protein expression via inhibition of NF-B activity, but also by regulating 
FANCD2 post-transcriptionally.  We therefore analyzed bortezomib-mediated regulation 
of the FA/BRCA pathway downstream of transcription. 
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 We first analyzed FANCD2 protein stability in bortezomib-treated cells.  Analysis 
of FANCD2 synthesis and degradation using stable isotopic labeling of amino acids in 
cell culture (SILAC) and mass spectrometry revealed that the reduction of FANCD2 
protein levels exhibited in bortezomib-treated cells is due to a drastic suppression of 
FANCD2 protein synthesis.  Of note, however, is that enhanced degradation of FANCD2 
protein was observed in bortezomib-treated cells as well, although the contribution of 
degradation to the decrease in overall FANCD2 protein levels after bortezomib treatment 
was minor compared to the contribution of inhibited synthesis.  We postulate that 
FANCD2 degradation in bortezomib-treated cells is due to incomplete inhibition of 
proteasomal activity by the low dose of drug utilized in these experiments or due to a 
non-proteasomal mechanism. 
 We next analyzed the contribution of cell cycle regulation to the inhibition of 
FANCD2.  FANCD2 monoubiquitination and foci formation is reported to be S-phase 
specific (156), and bortezomib is known to reduce the percentage of cells in S-phase 
(188-189).  Melphalan was found to arrest cells in the S-phase of the cell cycle.  
Bortezomib, on the other hand, induces a G0/G1 arrest, and can overcome the melphalan-
induced S-phase arrest.  Furthermore, ATR activation was inhibited after eight hours 
treatment with bortezomib, which, incidentally, is the same amount of time that cells are 
pre-treated with bortezomib before the addition of melphalan in the studies described 
above.  ATR is typically activated following DNA damage and induces an S-phase cell 
cycle checkpoint, leading to cell cycle arrest (195).  This kinase also phosphorylates 
FANCA, FANCD2, FANCI, and FANCM, and these phosphorylation events are critical 
for the activation of the FA/BRCA pathway (64, 151, 155, 210).  Based on these results, 
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we conclude that bortezomib overcomes melphalan-induced S-phase arrest via inhibition 
of ATR activation.  Curiously, bortezomib-treated cells do arrest, and we speculate that 
ATM kinase activity is not inhibited by bortezomib and can therefore compensate for the 
lack of ATR function and induce the observed G0/G1 cell cycle arrest.  In support of this 
theory, two separate labs have reported that ATM activity is not affected by proteasome 
inhibition (176, 211).  
 Finally, in a separate set of studies, we analyzed miRNA expression following 
bortezomib treatment.  MiRNAs bind to mRNA and repress translation without actually 
cleaving the mRNA itself (193-194).  We therefore hypothesized that the drastic decrease 
in FANCD2 expression could be due to upregulation of a miRNA that targets and thus 
represses FANCD2.  Based on microarray analysis of miRNA expression in bortezomib- 
versus control-treated cells, we identified two miRNAs that could potentially target 
FANCD2 mRNA, specifically, hsa-miR-23a and hsa-miR-27.  Further analysis of these 
miRNAs revealed that they do not function by targeting FANCD2.  A total of 33 
miRNAs were differentially expressed in bortezomib-treated cells, however, and it is 
plausible that these miRNAs may indirectly inhibit FANCD2 protein expression by 
targeting upstream mediators of the FA/BRCA pathway.  
 In summary, we have shown that bortezomib inhibits FA/BRCA pathway 
expression.  FANCD2 protein synthesis is inhibited in bortezomib-treated cells, and this 
inhibition is likely due to the combined effects of inhibition of NF-B, which we 
determined is a transcriptional activator of the FA/BRCA pathway, and bortezomib-
induced cell cycle arrest.  Overall, the results presented in this dissertation show that drug 
response and resistance in MM, and possibly other cancers, is mediated by the FA/BRCA 
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DNA damage repair pathway.  Therefore, we believe that targeting the FA/BRCA 
pathway to inhibit DNA damage repair, either directly or indirectly via inhibition of NF-
B or ATR activation, is vital for reversing, or possibly circumventing, drug resistance in 
multiple myeloma and possibly other cancers.         
 
Future Directions 
 We recently demonstrated that FA/BRCA pathway members are overexpressed in 
melphalan resistant cells, and causative for this resistance (3-4).  Additionally, other labs 
have reported that members of the FA/BRCA pathway mediate sensitivity to cisplatin, 
BCNU, and TMZ in different tumor types as well (170, 172-175).  In the Part I of this 
dissertation, we show that FA/BRCA pathway genes are also overexpressed in prostate 
and ovarian cancer cell lines selected for resistance to melphalan and cisplatin, 
respectively.  Conversely, we found that cells selected for resistance to topoisomerase II 
inhibitors do not show this same pattern of global overexpression of FA/BRCA pathway 
genes.  Instead, these resistant cells selectively overexpress FANCF.  It is known that all 
members of the FA core complex must be functional in order for ID complex activation, 
but the relative contribution of upregulation of one FA protein is unclear.  Therefore, we 
propose experiments that will examine the contribution of overexpression of FANCF to 
acquired resistance to topoisomerase II inhibitors.  First, we propose to transfect 
8226/Dox40 and 8226/MR20 cells with siRNAs specific to FANCF, and subsequently 
analyze sensitivity to doxorubicin and mitoxantrone, respectively, in siRNA-transfected 
cells compared to control-transfected cells and the drug sensitive 8226/S cells.  If FANCF 
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does contribute to acquired drug resistance in the 8226/Dox 40 and 8226/MR20 cells, 
depletion of FANCF should enhance drug sensitivity.   
 It is possible that FANCF is functioning both inside and outside of the FA/BRCA 
pathway.   Therefore, we also propose to examine FANCF protein interactions in drug 
sensitive and resistant cells by immuno-precipitation using a FANCF-specific antibody.  
Since FANCF is a flexible adaptor protein important for stabilizing interactions between 
other core complex proteins, the results may reveal enhanced interactions between 
FANCF and other FANC proteins in the drug resistant cells.  Alternatively, comparison 
of FANCF binding partners in the drug sensitive and resistant cells may reveal novel 
interactions between FANCF and non-FA pathway proteins that contribute to drug 
resistance.  Additionally, since demethylation of FANCF is known to contribute to drug 
resistance (173), we propose to examine the methylation status of FANCF in the drug 
sensitive and resistant cell lines. 
 Studies are also proposed to analyze the role of the FA/BRCA pathway in cell 
adhesion-mediated drug resistance (CAM-DR).  In this dissertation, we demonstrate that 
the NF-B subunits RelB and p50 regulate FA/BRCA pathway members.  Furthermore, 
RelB and p50 DNA binding activity is enhanced in cells adhered to fibronectin (FN) (58).  
We therefore hypothesize that FA/BRCA pathway expression is augmented when cells 
are adhered to FN, and upregulation of this pathway contributes to the CAM-DR 
phenotype.  First, we propose analyzing FA/BRCA pathway protein expression in cells 
adhered to FN to determine if basal expression of FA proteins is enhanced upon 
adhesion.  Also, since melphalan activates the FA/BRCA pathway, it will be important to 
analyze FA protein levels in FN-adhered myeloma cells treated with melphalan.  If FA 
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proteins are indeed upregulated by FN adhesion, using siRNAs to inhibit expression of 
these proteins is proposed to determine the contribution of this overexpression to drug 
resistance. 
 We also propose to analyze the factors that regulate FA/BRCA pathway 
expression in the absence of NF-B.  As seen in Part III of this dissertation, inhibition of 
NF-B with the BMS-345541 compound transiently reduced FA/BRCA pathway mRNA 
expression, but levels of expression oscillated throughout time.  Theoretically, once NF-
B is inhibited, other transcription factors will take over and transcriptionally activate 
this pathway.  Therefore, we propose stably expressing IB in 8226/S and 8226/LR5 
cells to inhibit NF-B activation, and analyzing the transcriptional regulation of 
FA/BRCA pathway members in NF-B-inhibited cells.  It will also be important to 
determine if these transcriptional regulators can fully compensate for NF-B loss, and we 
propose analyzing sensitivity to melphalan in the NF-B inhibited cells. We first propose 
analyzing Rb/E2F function in these cells, as it has been reported that this family of 
transcription factors regulates transcription of members of the FA/BRCA pathway (207).  
Furthermore, inhibiting E2F in the NF-B-inactive cells would be interesting to 
determine if FA/BRCA pathway expression can be completely abolished and if inhibition 
of both NF-B and E2F/Rb greatly enhances drug sensitivity. 
 In Part IV of this dissertation, we show that melphalan induces an S-phase arrest, 
whereas bortezomib causes an arrest in G0/G1.  Furthermore, pre-treatment with 
bortezomib is able to overcome the melphalan-induced S-phase arrest, and combination-
treated cells also arrest in G0/G1.  We also show that ATR activation is inhibited in 
bortezomib-treated cells.  We hypothesize that ATM is activated by bortezomib, and that 
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this kinase is responsible for activation of the G1 cell cycle checkpoint leading to the 
G0/G1 arrest seen in bortezomib-treated cells.  It will be important to look at ATM 
activity in bortezomib-treated cells.  Likewise, ATM and ATR activation should be 
analyzed in melphalan-stimulated cells as well as in cells treated with the combination of 
bortezomib plus melphalan.  Similarly, the activity of Chk1 and Chk2 kinases, two 
downstream mediators of ATM and ATR, should also be analyzed in cells treated with 
bortezomib and melphalan.   
 An interesting report by Alan D‟Andrea‟s group showed that inhibition of the 
FA/BRCA pathway led to “hyper-activation” of Chk1, and this activation compensates 
for lack of FA-mediated DNA repair.  Therefore, we hypothesize that combining 
bortezomib with Chk1 inhibitors will greatly enhance cytotoxicity by inhibiting both FA- 
and Chk1-mediated repair.  We propose analyzing the combined effects of bortezomib 
with the Chk1-inhibitor Go6976 via combination index analysis in 8226/S and 8226/LR5 
drug-treated cells.  Along similar lines, we also propose to analyze the combinatorial 
effects of bortezomib and PARP inhibitors.  As mentioned in the discussion, BRCA1- and 
BRCA2-deficient cells are extremely sensitive to PARP inhibition (199-200), and we 
believe that exploiting the FA/BRCA pathway-inhibitory effects of bortezomib by 
treatment with PARP inhibitors will greatly enhance the cyctotoxic effects of bortezomib. 
 Analysis of FA/BRCA pathway expression in myeloma cells treated with the 
second-generation proteasome inhibitors carfilzomib and NPI-0052 may also be 
important.  These agents irreversibly inhibit the proteasome and can overcome 
boretezomib resistance (29, 81).  It is plausible that these drugs can inhibit the FA/BRCA 
pathway more effectively and for a longer period of time than can bortezomib.          
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 Finally, it may also prove worthwhile to further analyze miRNA expression 
following bortezomib treatment.  Although bortezomib treatment may not alter 
expression of miRNAs that directly target FA mRNAs, it is conceivable that bortezomib 
treatment changes expression of miRNAs that target proteins upstream of this pathway.  
Furthermore, miRNA analysis of drug sensitive versus drug resistant cells may be 
important for determining if differential expression of specific miRNAs contributes to 
acquired drug resistance. 
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